

**Matthew W. Johnson, Ph.D.**  
Professor

**Department of Psychiatry and Behavioral Sciences**  
**Behavioral Pharmacology Research Unit**  
5510 Nathan Shock Drive  
Baltimore, MD 21224-6823  
410-550-0056 T  
410-550-0030 F  
mwj@jhu.edu



February 10, 2022

Submitted Via [www.regulations.gov](http://www.regulations.gov)

Drug Enforcement Administration  
Attn: DEA FR Representative/DPW  
8701 Morrisette Drive  
Springfield, Virginia 22152

Re: Docket No. DEA-623

Dear DEA Federal Register Representative:

I am taking this opportunity to make a formal submission to the Drug Enforcement Administration (DEA) in my individual capacity as a researcher in behavioral pharmacology and investigational clinical pharmacology. After evaluating the DEA's Notice of Proposed Rulemaking for Schedules of Controlled Substances that the DEA published on January 14, 2022, in the Federal Register, it became apparent to me that this submission was necessary to ensure a complete and accurate record regarding 4-Hydroxy-*N,N*-diisopropyltryptamine (4-OH-DiPT), which the DEA is proposing to place into Schedule I of the Controlled Substances Act (CSA). I write to argue against this placement.

In my personal capacity as a leading researcher in this field for over 17 years, I am not convinced by the DEA's underlying rationales for proposing to schedule 4-OH-DiPT and by the very serious implications that would befall me and my fellow clinical researchers in the field if the DEA were to actually move forward with its scheduling proposal on 4-OH-DiPT. As one of the world's most published scientists on the human effects of psychedelics who has received continuous NIH funding as Principal Investigator since 2009, I have been directly involved in a myriad of studies evaluating the clinical potential of investigational new compounds similar to 4-OH-DiPT in that they may hold significant therapeutic potential in treating patients across a range of life-threatening diseases and medical conditions. As detailed in one of the seminal publications in the field (Johnson et al., *Neuropharmacology* (2018) 1-24), placing a compound that is in the middle of ongoing drug development such as 4-OH-DiPT in Schedule I of the CSA can effectively bring these pivotal drug development initiatives to a halt by erecting difficult barriers for academic and other researchers involved in their clinical development. I am very familiar with these research-related considerations from my tenure as a Professor of Psychiatry and Behavioral Sciences at Johns

Hopkins as well as my service as the 2019 President of the Psychopharmacology and Substance Abuse Division of the American Psychological Association. Attached for the DEA's reference is a copy of my CV.

Under the CSA, its implementing regulations, and the Food and Drug Administration's (FDA's) Guidance for Industry, "Assessment of Abuse Potential of Drugs" (<https://www.fda.gov/media/116739/download>), the scheduling process for new drugs begins with FDA's review and evaluation of the voluminous data submitted by a sponsor in its new drug application ("NDA") if the proposed drug product contains a drug substance(s) that has central nervous system (CNS) activity and produces euphoria (or other changes in mood), hallucinations, and effects consistent with CNS depressants or stimulants. Any such drug substance that is CNS-active in a new drug product undergoes a thorough assessment of its abuse potential by FDA based upon extensive data from a broad range of studies. In the case of a compound such as 4-OH-DiPT, which has shown potential to be an innovative therapeutic breakthrough, that post-NDA submission FDA assessment of abuse potential should be the trigger of any scheduling decision. Until that time, given the extent to which undertreated and treatment-resistant mental and behavioral disorders such as treatment-resistant depression remain serious problems at the personal and societal levels in the US and globally (Belouin and Henningfield, 2018), the need for continued research on the therapeutic potential of compounds like 4-OH-DiPT is urgent and should proceed without artificial regulatory barriers that impede researchers' ability to conduct clinical studies.

Indeed, the importance of enabling ongoing research and development to continue unimpeded by CSA scheduling is all the more critical in the case of 4-OH-DiPT. The novel profile of 4-OH-DiPT that has emerged from the peer-review literature reflects unique properties (Rickli et al., *European Neuropsychopharmacology* (2016) 26:1327-37), including a novel receptor profile directed at neuro plasticity (Ly et al., *Cell Rep.* (2018), 23(11):3170-3182), and a very brief duration of action (Tittarelli et al., *Current Neuropharmacology* (2015) 13:26-46).

Separate and apart from the therapeutic potential of 4-OH-DiPT, the single most important reason for not placing 4-OH-DiPT in Schedule I of the CSA is the absence of any current data and information on its abuse potential. Instead of citing contemporaneous analyses and recommendations from the HHS Assistant Secretary of Health in its January 2022 notice of proposed rulemaking, the DEA instead relied exclusively on a scientific and medical evaluation of prepared by the former Assistant Secretary in 2012.

Not only is the Assistant Secretary's 2012 evaluation outdated as to 4-OH-DiPT, but it also relies on incomplete and erroneous analyses as to the actual abuse or potential for abuse of 4-OH-DiPT. Even in 2012, there was no clear evidence of physical dependence and withdrawal in preclinical studies, and there is nothing in the DEA's notice of proposed rulemaking that indicates that any such evidence has been seen in the ensuing ten years. In addition, in 2012, none of the major drug surveillance systems indicate rates of abuse, emergency department reports, or treatment seeking in youth or adults, and, again, DEA has not cited any evidence of that in the drug surveillance systems over the past ten years. Similarly, as to drug encounters in the United States

for 4-OH-DiPT, Table 5 of the DEA's Background, Data, and Analysis report reflects that there have been only a total of *five (5)* NFLIS drug encounters – since 2009. This uniquely *small* number of encounters over the past 13 years alone reflects that 4-OH-DiPT does not pose an identifiable and substantive abuse risk to public health. This inescapable conclusion is reinforced by DEA's own recognition in that report that 4-OH-DiPT is "available for purchase from legitimate chemical companies because [it is] used in scientific research [and [n]o evidence of diversion is apparent from these companies." In short, it could not reasonably be concluded in 2012 -- and it certainly cannot be concluded ten years later in 2022 -- that 4-OH-DiPT is readily available to be abused or actually being illicitly diverted or abused.

Accordingly, in my expert opinion, there is no basis for placing 4-OH-DiPT in Schedule I of the CSA. Instead, the DEA should remove 4-OH-DiPT from this rulemaking proceeding and not place it in CSA Schedule I.

Thank you for considering this submission and my personal views on this critically important and potentially innovative therapeutic compound and its ongoing research and development.

As I do in my research publications on psychedelics, I declare the following interests relevant to the DEA's rulemaking: I am in paid advisory relationships with the following organizations regarding the medical development of psychedelics and related compounds: AJNA Labs LLC, AWAKN Life Sciences Inc., Beckley Psychedelic Ltd., Entheogen Biomedical Corp., Field Trip Psychedelics Inc., Mind Medicine Inc., and Otsuka Pharmaceutical Development & Commercialization Inc.

Best regards,



Matthew Wayne Johnson, Ph.D.

Attachment (Curriculum Vitae)

CURRICULUM VITAE  
The Johns Hopkins University School of Medicine

Matthew W. Johnson, Ph.D.

November 15, 2021

### Current Appointments

#### University

- 2020-present    Professor  
Behavioral Pharmacology Research Unit  
Department of Psychiatry and Behavioral Sciences  
Johns Hopkins University School of Medicine
- 2021-present    Endowed Professorship: The Susan Hill Ward Professor of Psychedelics & Consciousness Research  
Johns Hopkins Center of Psychedelics and Consciousness Research  
Department of Psychiatry and Behavioral Sciences  
Johns Hopkins University School of Medicine

### Personal Data

Behavioral Pharmacology Research Unit  
Johns Hopkins University School of Medicine  
5510 Nathan Shock Drive  
Baltimore, MD 21224-6823  
Tel: (410) 550-0056  
Fax: (410) 550-0030  
E-mail: mwj@jhu.edu

### Education and Training

#### Undergraduate

1998            B.S., Psychology, Eastern Oregon University, La Grande, Oregon

#### Doctoral/graduate

- 2002            M.A., General/Experimental Psychology, Biobehavioral Specialization, University of Vermont, Burlington, Vermont
- 2004            Ph.D., General/Experimental Psychology, Biobehavioral Specialization, University of Vermont, Burlington, Vermont

#### Postdoctoral

2004-2007    Postdoctoral Fellowship, Johns Hopkins University School of Medicine, Primary Mentor: Roland Griffiths, Ph.D.

### Professional Experience

- 2007-2009    Instructor, Johns Hopkins University School of Medicine, Baltimore, Maryland
- 2009-2013    Assistant Professor, Johns Hopkins University School of Medicine, Baltimore, Maryland
- 2013-2020    Associate Professor, Johns Hopkins University School of Medicine, Baltimore, Maryland
- 2020-Present    Professor, Johns Hopkins University School of Medicine, Baltimore, Maryland

### PUBLICATIONS:

1. **Johnson MW**, Ettinger RH. Active cocaine immunization attenuates the discriminative properties of cocaine. *Exp Clin Psychopharmacol.* 2000;8(2):163.
2. **Johnson MW**, Bickel WK. Within-subject comparison of real and hypothetical money rewards in delay discounting. *J Exp Anal Behav.* 2002;77(2):129-46.
3. **Johnson MW**, Bickel WK. The behavioral economics of cigarette smoking: The concurrent presence of a substitute and an independent reinforcer. *Behav Pharmacol.* 2003;14(2):137-44.
4. Baker F, **Johnson MW**, Bickel WK. Delay discounting in current and never-before cigarette smokers: similarities and differences across commodity, sign, and magnitude. *J Abnorm Psychol.* 2003 Aug;112(3):382.
5. Baker F, **Johnson MW**, Bickel WK. Decision-making in state lotteries: Half now or all of it later? *Psychon Bull Rev.*

- 2003;10(4):965-70.
6. **Johnson MW**, Bickel WK, Kirshenbaum AP. Substitutes for tobacco smoking: a behavioral economic analysis of nicotine gum, denicotinized cigarettes, and nicotine-containing cigarettes. *Drug Alcohol Depend.* 2004;74(3):253-64.
  7. Griffiths, RR, **Johnson MW**. Relative abuse liability of hypnotic drugs: a conceptual framework and algorithm for differentiating among compounds. *J Clin Psychiatry.* 2005;66(supplement 9):31-41.
  8. **Johnson MW**, Griffiths RR. Ramelteon: A viewpoint by Matthew W. Johnson and Roland R. Griffiths. *CNS Drugs.* 2005;19(12):1066-7.
  9. Yi R, **Johnson MW**, Bickel WK. Relationship between cooperation in an iterated prisoner's dilemma game and the discounting of hypothetical outcomes. *Learn Behav.* 2005;33(3):324-36.
  10. Heil SH, **Johnson MW**, Higgins ST, Bickel WK. Delay discounting in currently using and currently abstinent cocaine-dependent outpatients and non-drug-using matched controls. *Addict Behav.* 2006;31(7):1290-4.
  11. **Johnson MW**, Bickel WK. Replacing relative reinforcing efficacy with behavioral economic demand curves. *J Exp Anal Behav.* 2006;85(1):73-93.
  12. **Johnson MW**, Suess PE, Griffiths RR. Ramelteon: A novel hypnotic lacking abuse liability and sedative adverse effects. *Arch Gen Psychiatry.* 2006;63(10):1149-57.
  13. **Johnson MW**, Bickel WK, Baker F. Moderate drug use and delay discounting: a comparison of heavy, light, and never smokers. *Exp Clin Psychopharmacol.* 2007;15(2):187.
  14. **Johnson MW**, Bickel WK. An algorithm for identifying nonsystematic delay-discounting data. *Exp Clin Psychopharmacol.* 2008;16(3):264-74.
  15. **Johnson MW**, Richards WA, Griffiths RR. Human hallucinogen research: Guidelines for safety. *J Psychopharmacol.* 2008;22(6):603-20.
  16. Yi R, **Johnson MW**, Giordano LA, Landes RD, Badger GJ, Bickel WK. The effects of reduced cigarette smoking on discounting future rewards: An initial evaluation. *Psychol Rec.* 2008;58(2):163.
  17. Griffiths RR, Richards WA, **Johnson MW**, McCann UD, Jesse R. Mystical-type experiences occasioned by psilocybin mediate the attribution of personal meaning and spiritual significance 14 months later. *J Psychopharmacol.* 2008;22(6):621-32.
  18. Kirshenbaum AP, **Johnson MW**, Schwarz SL, Jackson ER. Response disinhibition evoked by the administration of nicotine and nicotine-associated contextual cues. *Drug Alcohol Depend.* 2009;105(1):97-108.
  19. **Johnson MW**, Bickel WK, Baker F, Moore BA, Badger GJ, Budney AJ. Delay discounting in current and former marijuana-dependent individuals. *Exp Clin Psychopharmacol.* 2010;18(1):99-107.
  20. **Johnson MW**, Strain EC, Griffiths RR. Effects of oral caffeine pretreatment on response to intravenous nicotine and cocaine. *Exp Clin Psychopharmacol.* 2010;18(4):305-15.
  21. **Johnson MW**, MacLean KA, Reissig CJ, Prisinzano TE, Griffiths RR. Human psychopharmacology and dose-effects of salvinorin A, a kappa opioid agonist hallucinogen present in the plant *Salvia divinorum*. *Drug Alcohol Depend.* 2011;115(1):150-5.
  22. Griffiths RR, **Johnson MW**, Richards WA, Richards BD, McCann U, Jesse R. Psilocybin occasioned mystical-type experiences: immediate and persisting dose-related effects. *Psychopharmacology.* 2011;218(4):649-65.
  23. MacLean KA, **Johnson MW**, Griffiths RR. Mystical experiences occasioned by the hallucinogen psilocybin lead to increases in the personality domain of openness. *J Psychopharmacol.* 2011;25(11):1453-61.
  24. **Johnson MW**, Sewell RA, Griffiths RR. Psilocybin dose-dependently causes delayed, transient headaches in healthy volunteers. *Drug Alcohol Depend.* 2012;123(1):132-40.
  25. **Johnson MW**. An Efficient Operant Choice Procedure for Assessing Delay Discounting in Humans: Initial Validation in Cocaine-Dependent and Control Individuals. *Exp Clin Psychopharmacol.* 2012;20(3):191-204.
  26. **Johnson MW**, Bruner NR. The Sexual Discounting Task: HIV risk behavior and the discounting of delayed sexual rewards in cocaine dependence. *Drug Alcohol Depend.* 2012;1(123):15-21.
  27. MacLean KA, **Johnson MW**, Reissig CJ, Prisinzano TE, Griffiths RR. Dose-related effects of salvinorin A in humans: dissociative, hallucinogenic, and memory effects. *Psychopharmacology.* 2013;226(2):381-92.
  28. MacLean KA, Leoutsakos JM, **Johnson MW**, Griffiths RR. Factor analysis of the mystical experience questionnaire: A study of experiences occasioned by the hallucinogen psilocybin. *J Sci Study Relig.* 2012;51(4):721-37.
  29. Reissig CJ, Carter LP, **Johnson MW**, Mintzer MZ, Klinedinst MA, Griffiths RR. High doses of dextromethorphan, an NMDA antagonist, produce effects similar to classic hallucinogens. *Psychopharmacology.* 2012;223(1):1-5.
  30. Carter LP, Reissig CJ, **Johnson MW**, Klinedinst MA, Griffiths RR, Mintzer MZ. Acute cognitive effects of high doses of dextromethorphan relative to triazolam in humans. *Drug Alcohol Depend.* 2013;128(3):206-13.
  31. Caspers MJ, Williams TD, Lovell KM, Lozama A, Butelman ER, Kreek MJ, **Johnson MW**, Griffiths R, MacLean K, Prisinzano TE. LC-MS/MS quantification of salvinorin A from biological fluids. *Anal Methods.* 2013;5(24):7042-8.
  32. **Johnson MW**, Griffiths RR. Comparative abuse liability of GHB and ethanol in humans. *Exp Clin Psychopharmacol.* 2013;21(2):112-23.

33. **Johnson MW, Bruner NR.** Test-retest reliability and gender differences in the sexual discounting task among cocaine-dependent individuals. *Exp Clin Psychopharmacol.* 2013;21(4):277-86.
34. McClure EA, Vandrey RG, **Johnson MW**, Stitzer ML. Effects of varenicline on abstinence and smoking reward following a programmed lapse. *Nicotine Tob Res.* 2013;15(1):139-48.
35. Vandrey R, **Johnson MW**, Johnson PS, Khalil MA. Novel drugs of abuse: a snapshot of an evolving marketplace. *Adolesc Psychiatry.* 2013;3(2):123-34.
36. Bickel WK, **Johnson MW**, Koffarnus MN, MacKillop J, Murphy JG. The behavioral economics of substance use disorders: reinforcement pathologies and their repair. *Annu Rev Clin Psychol.* 2014;10:641-77.
37. Bruner NR, **Johnson MW.** Demand curves for hypothetical cocaine in cocaine-dependent individuals. *Psychopharmacology.* 2014;231(5):889-97.
38. Dariotis JK, **Johnson MW.** Sexual discounting among high-risk youth ages 18-24: implications for sexual and substance use risk behaviors. *Exp Clin Psychopharmacol.* 2014;23(1):49-58.
39. Garcia-Romeu AP, Griffiths RR, **Johnson MW.** Psilocybin-occasioned mystical experiences in the treatment of tobacco addiction. *Curr Drug Abuse Rev.* 2014;7(3):157-64.
40. Hendricks PS, Clark CB, **Johnson MW**, Fontaine KR, Cropsey KL. Hallucinogen use predicts reduced recidivism among substance-involved offenders under community corrections supervision. *J Psychopharmacol.* 2014;28(1):62-6.
41. Herrmann ES, Hand DJ, **Johnson MW**, Badger GJ, Heil SH. Examining delay discounting of condom-protected sex among opioid-dependent women and non-drug-using control women. *Drug Alcohol Depend.* 2014;144:53-60.
42. **Johnson MW**, Garcia-Romeu AP, Cosimano MP, Griffiths RR. Pilot study of the 5-HT<sub>2A</sub>R agonist psilocybin in the treatment of tobacco addiction. *J Psychopharmacol.* 2014;28(11):983-92.
43. Johnson PS, **Johnson MW.** Investigation of "bath salts" use patterns within an online sample of users in the United States. *J Psychoactive Drugs.* 2014;46(5):369-78.
44. Barrett FS, **Johnson MW**, Griffiths RR. Validation of the revised Mystical Experience Questionnaire in experimental sessions with psilocybin. *J Psychopharmacol.* 2015;29(11):1182-90.
45. Duke AN, **Johnson MW**, Reissig CJ, Griffiths RR. Nicotine reinforcement in never-smokers. *Psychopharmacology.* 2015;232(23):4243-52.
46. Hendricks PS, Thorne CB, Clark CB, Coombs DW, **Johnson MW.** Classic psychedelic use is associated with reduced psychological distress and suicidality in the United States adult population. *J Psychopharmacol.* 2015;29(3):280-8.
47. Hendricks PS, **Johnson MW**, Griffiths RR. Psilocybin, psychological distress, and suicidality. *J Psychopharmacol.* 2015;29(9):1041-3.
48. Herrmann ES, Johnson PS, **Johnson MW.** Examining delay discounting of condom-protected sex among men who have sex with men using crowdsourcing technology. *AIDS Behav.* 2015;19(9):1655-65.
49. **Johnson MW**, Bruner NR, Johnson PS. Cocaine dependent individuals discount future rewards more than future losses for both cocaine and monetary outcomes. *Addict Behav.* 2015;40:132-6.
50. Johnson PS, Herrmann ES, **Johnson MW.** Opportunity costs of reward delays and the discounting of hypothetical money and cigarettes. *J Exp Anal Behav.* 2015;103(1):87-107.
51. **Johnson MW**, Johnson PS, Herrmann ES, Sweeney MM. Delay and probability discounting of sexual and monetary outcomes in individuals with cocaine use disorders and matched controls. *PLoS One.* 2015;10(5):e0128641.
52. Maqueda AE, Valle M, Addy PH, Antonijoan RM, Puentes M, Coimbra J, Ballester MR, Garrido M, González M, Claramunt J, Barker S, **Johnson MW**, Griffiths RR, Riba J. Salvinorin-A induces intense dissociative effects, blocking external sensory perception and modulating interoception and sense of body ownership in humans. *Int J Neuropsychopharmacol.* 2015;18(12):1-14.
53. Rass O, Pacek LR, Johnson PS, **Johnson MW.** Characterizing use patterns and perceptions of relative harm in dual users of electronic and tobacco cigarettes. *Exp Clin Psychopharmacol.* 2015;23(6):494-503.
54. Rass O, Schacht RL, Buckheit K, **Johnson MW**, Strain EC, Mintzer MZ. A randomized controlled trial of the effects of working memory training in methadone maintenance patients. *Drug Alcohol Depend.* 2015;156:38-46.
55. Rass O, Umbricht A, Bigelow GE, Strain EC, **Johnson MW**, Mintzer MZ. Topiramate impairs cognitive function in methadone-maintained individuals with concurrent cocaine dependence. *Psychol Addict Behav.* 2015;29(1):237-46.
56. Sessa B, **Johnson MW.** Can psychedelic compounds play a part in drug dependence therapy? *Br J Psychiatry.* 2015;206(1):1-3.
57. Tupper KW, Wood E, Yensen R., **Johnson MW.** Psychedelic medicine: A re-emerging therapeutic paradigm. *CMAJ.* 2015;187(14):1054-9.
58. Barrett FS, Bradstreet MP, Leoutsakos JS, **Johnson MW**, Griffiths RR. The Challenging Experience Questionnaire: Characterization of challenging experiences with psilocybin mushrooms. *J Psychopharmacol.* 2016;30(12):1279-95.
59. Bogenschutz MP, **Johnson MW.** Classic hallucinogens in the treatment of addictions. *Prog Neuropsychopharmacol Biol Psychiatry.* 2016;64:250-8.

60. Carbonaro TM, Bradstreet MP, Barrett FS, MacLean KA, Jesse R, **Johnson MW**, Griffiths, RR. Survey study of challenging experiences after ingesting psilocybin mushrooms: Acute and enduring positive and negative consequences. *J Psychopharmacol*. 2016; 30(12):1268-78.
61. Dunn KE, Barrett FS, Herrmann ES, Plebani JG, Sigmon SC, **Johnson MW**. Behavioral Risk Assessment for Infectious Diseases (BRAID): Self-report instrument to assess injection and noninjection risk behaviors in substance users. *Drug Alcohol Depend*. 2016;168:69-75.
62. Griffiths RR, **Johnson MW**, Carducci MA, Umbricht A, Richards WA, Richards BD, Cosimano MP, Klinedinst MA. Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial. *J Psychopharmacol*. 2016;30(12):1181-97.
63. Herrmann ES, Johnson PS, **Johnson MW**. Commentary on: Does attractiveness influence condom use intentions in heterosexual men? An experimental study. *BMJ Open* 2016;6:e010883.
64. **Johnson MW**, MacLean KA, Caspers MJ, Prisinzano TE, Griffiths RR. Time course of pharmacokinetic and hormonal effects of inhaled high-dose salvinorin A in humans. *J Psychopharmacol*. 2016;30(4):323-9.
65. Johnson PS, Sweeney MM, Herrmann ES, **Johnson MW**. Alcohol increases delay and probability discounting of condom-protected sex: A novel vector for alcohol-related HIV transmission. *Alcohol Clin Exp Res*. 2016;40(6):1339-1350.
66. Koffarnus MN, **Johnson MW**, Thompson-Lake DG, Wesley MJ, Lohrenz T, Montague PR, Bickel WK. Cocaine-dependent adults and recreational cocaine users are more likely than controls to choose immediate unsafe sex over delayed safer sex. *Exp Clin Psychopharmacol*. 2016;24(4):297-304.
67. Maqueda AE, Valle M, Addy PH, Antonijoan RM, Puentes M, Coimbra J, Ballester MR, Garrido M, González M, Claramunt J, Barker S, Lomnicka I, Waguespack M, **Johnson MW**, Griffiths RR, Riba J. Naltrexone but not ketanserin antagonizes the subjective, cardiovascular and neuroendocrine effects of salvinorin-A in humans. *Int J Neuropsychopharmacol*. 2016;19(7):1-13.
68. Meredith SE, Sweeney MM, Johnson PS, **Johnson MW**, Griffiths RR. Weekly energy drink use is positively associated with delay discounting and risk behavior in a nationwide sample of young adults. *J Caffeine Res*. 2016;6(1):10-19.
69. Paul MJ, Chisolm MS, **Johnson MW**, Vandrey RG, Dredze M. Assessing the validity of online drug forums as a source for estimating demographic and temporal trends in drug use. *J Addict Med*. 2016;10(5):324-30.
70. Sheffer CE, Mackillop J, Fernandez A, Christensen D, Bickel WK, **Johnson MW**, Panissidi L, Pittman J, Franck CT, Williams J, Mathew M. Initial examination of priming tasks to decrease delay discounting. *Behavioural processes*. 2016;128:144-52.
71. Sweeney MM, Rass O, Johnson PS, Strain EC, Berry MS, Fishman MJ, Rebok GW, Vo HT, Munro CA, Mintzer MZ, **Johnson MW**. Initial feasibility and validity of a prospective memory training program in a substance use treatment population. *Exp Clin Psychopharmacol*. 2016;24(5):390-9.
72. Tompkins DA, Johnson PS, Smith MT, Strain EC, Edwards RR, **Johnson MW**. Temporal preference in individuals reporting chronic pain: Discounting of delayed pain-related and monetary outcomes. 2016;157(8):1724-1732.
73. Barratt FS, **Johnson MW**, Griffiths RR. Neuroticism is associated with challenging experiences with psilocybin mushrooms. *Pers Individ Dif*. 2017;117:155-60.
74. Collado A, Johnson PS, Loya JM, **Johnson MW**, Yi R. Discounting of condom-protected sex as a measure of high-risk for sexually transmitted infection among college students. *Arch Sex Behav*. 2017;46:2187-95.
75. **Johnson MW**, Garcia-Romeu AP, Griffiths RR. Long-term follow-up of psilocybin-facilitated smoking cessation. *Am J Drug Alcohol Abuse*. 2017;43(1):55-60.
76. **Johnson MW**, Herrmann ES, Sweeney MM, LeComte RS, Johnson PS. Cocaine administration dose-dependently increases sexual desire and decreases condom use likelihood: The role of delay and probability discounting in connecting cocaine with HIV. *Psychopharmacology*. 2017;234(4):599-612.
77. **Johnson MW**, Garcia-Romeu AP, Johnson PS, Griffiths RR. An online survey of tobacco smoking cessation associated with naturalistic psychedelic use. *J Psychopharmacol*. 2017;31(7):841-850.
78. **Johnson MW**, Griffiths RR. Potential therapeutic effects of psilocybin. *Neurotherapeutics*. 2017;14:734-40.
79. **Johnson MW**, Johnson PS, Rass O, Pacek LR. Behavioral economic substitutability of e-cigarettes, tobacco cigarettes, and nicotine gum. *J Psychopharmacol*. 2017;31(7):851-860.
80. Horan WP, **Johnson MW**, Green MF. Altered experiential, but not hypothetical, delay discounting in schizophrenia. *J Abnorm Psychol*. 2017;126(3):301-11.
81. Herrmann ES, Johnson PS, Bruner NR, Vandrey R, and **Johnson MW**. Morning administration of oral methamphetamine dose-dependently disrupts nighttime sleep in recreational stimulant users. *Drug Alcohol Depend*. 2017;178:291-295.
82. Nichols DE, **Johnson MW**, Nichols CD. Psychedelics as medicines: An emerging new paradigm. *Clin Pharmacol Ther*. 2017;101:209-19.

83. Pacek LR, Rass O, **Johnson MW**. Knowledge about smoking and nicotine among smokers living with HIV: Implications for tobacco regulatory science policy. *Addictive Behaviors*. 2017;65:81-86.
84. Pacek LR, Rass O, **Johnson MW**. Positive smoking cessation-related interactions with HIV care providers increase the likelihood of interest in cessation among HIV-positive cigarette smokers. *Aids Care*. 2017;29:1309-14.
85. Saleemi S, Pennybaker SJ, Wooldridge M, **Johnson MW**. Who is "Molly"? MDMA-adulterants by product name and the impact of harm reduction services at raves. *J Psychopharmacol*. 2017;31(8):1056-60.
86. Berry MS, **Johnson MW**. Does being drunk or high cause HIV sexual risk behavior? A systematic review of drug administration studies. *Pharmacol Biochem Behav*. 2018;164:125-38.
87. Carbonaro TM, **Johnson MW**, Hurwitz E, Griffiths RR. Double-blind comparison of the two hallucinogens psilocybin and dextromethorphan: similarities and differences in subjective experiences. *Psychopharmacology*. 2018;235(2):521-34.
88. Griffiths RR, **Johnson MW**, Richards WA, Richards BD, Jesse R, MacLean KA, Barrett FS, Cosimano MP, Klinedinst MA. Psilocybin-occasioned mystical-type experience in combination with meditation and other spiritual practices produces enduring positive changes in psychological functioning and in trait measures of prosocial attitudes and behaviors. *J Psychopharmacol*. 2018;32(1):49-69.
89. **Johnson MW**. Psychiatry might need some psychedelic therapy. Introduction to issue: The renaissance in psychedelic research. *Int Rev Psychiatry*. 2018;30(4):285-90.
90. **Johnson MW**, Griffiths RR, Hendricks PS, Henningfield. The abuse potential of medical psilocybin according to the 8 factors of the Controlled Substances Act. *Neuropharmacology*. 2018;142:143-66.
91. **Johnson MW**, Griffiths RR, Hendricks PS, Henningfield. Setting the record straight on medical psilocybin. *Scientific American, Observations*. 2018; August 23.
92. **Johnson MW**, Hendricks PS, Barrett FS, Griffiths RR. Classic Psychedelics: An integrative review of epidemiology, therapeutics, mystical experience, and brain network function. *Pharmacology & Therapeutics*. 2018;S0163-7258(18):30215-8.
93. Noorani, T, Garcia-Romeu A, Swift T, Griffiths RR, **Johnson MW**. Psychedelic therapy for smoking cessation: Qualitative analysis of participant accounts. *J Psychopharmacol*. 2018;32(7):756-69.
94. Sweeney MM, Rass O, DiClemente C, Schacht RL, Vo HT, Fishman MJ, Leoutsakos JS, Mintzer MZ, **Johnson MW**. Working memory training for adolescents with cannabis use disorders: A randomized controlled trial. *J Child Adolesc Subst Abuse*. 2018;27(4):211-26.
95. Tompkins DA, Huhn AS, Johnson PS, Smith MT, Strain EC, Edwards RR, **Johnson MW**. To take or not to take: The association between perceived addiction risk, expected analgesic response, and likelihood of trying novel pain relievers in self-identified chronic pain patients. *Addiction*. 2018;113(1):67-79.
96. Barrett FS, Carbonaro TM, Hurwitz E, **Johnson MW**, Griffiths RR. Double-blind comparison of the two hallucinogens psilocybin and dextromethorphan: effects on cognition. *Psychopharmacology*. 2018;235(10):2915-27.
97. Berry MS, Johnson PS, Collado A, Loya JM, Yi R, **Johnson MW**. Sexual probability discounting: A mechanism for sexually transmitted infection among undergraduate students. *Arch Sex Behav*. 2019;48(2):495-505.
98. Pacek LR, McClernon FJ, Rass R, **Johnson MW**. Perceived risk of developing smoking-related disease among persons living with HIV. *AIDS Care*. 2018;30(10):1329-34.
99. Garcia-Romeu A, Davis AK, Erowid F, Erowid E, Griffiths RR, **Johnson MW**. Cessation and reduction in alcohol consumption and misuse after psychedelic use. *J Psychopharmacol*. 2019;33(9):1088-101.
100. Griffiths RR, Hurwitz ES, Davis AK, **Johnson MW**, Jesse R. Survey of subjective "God encounter experiences": Comparisons among naturally occurring experiences and those occasioned by the classic psychedelics psilocybin, LSD, ayahuasca, or DMT. *PLoS ONE*. 2019;14(4): e0214377.
101. Mayo-Wilson LJ, Glass NE, Ssewamala FM, Linnemayr S, Coleman J, Timbo F, **Johnson MW**, Davoust M, Labrique A, Yenokyan G, Dodge B, Latkin C. Microenterprise intervention to reduce sexual risk behaviors and increase employment and HIV preventive practices in economically-vulnerable African-American young adults (EMERGE): protocol for a feasibility randomized clinical trial. *Trials*. 2019;20(1):439.
102. Pacek LR, Berry MS, Rass O, Mercincavage M, McClernon FJ, **Johnson MW**. Graphic warning labels affect hypothetical cigarette purchasing behavior among smokers living with HIV. *Int J Environ Res Public Health*. 2019;16(18). pii: E3380.
103. Sweeney MM, Berry MS, Johnson PS, Herrmann ES, Meredith SE, **Johnson MW**. Demographic and sexual risk predictors of delay discounting of condom-protected sex in a naturalistic setting. *Psychol Health*. 2019;16:1-21.
104. Bergeria CL, Dolan SB, **Johnson MW**, Campbell CM, Dunn KE. Evaluating the co-use of opioids and cannabis for pain among current users using hypothetical purchase tasks. *Journal of Psychopharmacology*. 2020;34(6):654-62.
105. Dolan SB, Berry MS, **Johnson MW**. Potential for limited reinforcing and abuse-related subjective effects of intranasal oxytocin. *J Psychopharmacol*. 2020;34(3):336-47.



106. Doss MK, May DG, **Johnson MW**, Clifton JM, Hedrick SL, Prisinzano TE, Griffiths RR, Barrett FS. The Acute Effects of the Atypical Dissociative Hallucinogen Salvinorin A on Functional Connectivity in the Human Brain. *Scientific reports*. 2020;10(1):1-12.
107. Garcia-Romeu A, Davis AK, Erowid E, Erowid F, Griffiths RR, **Johnson MW**. Persisting reductions in cannabis, opioid, and stimulant misuse after naturalistic psychedelic use: An online survey. *Frontiers in Psychiatry*. 2020;10:955.
108. **Johnson MW**, Bruner NR, Johnson PS, Silverman K, Berry MS. Randomized controlled trial of d-cycloserine in cocaine dependence: Effects on contingency management and cue-induced cocaine craving. *Exp Clin Psychopharmacol*. 2020;28(2):157-68.
109. Carbonaro TM, **Johnson MW**, Griffiths RR. Subjective features of the psilocybin experience that may account for its self-administration by humans: a double-blind comparison of psilocybin and dextromethorphan. *Psychopharmacology*. 2020;237(8):2293-304.
110. Cox DJ, Dolan SB, Johnson PS, **Johnson MW**. Delay and probability discounting in cocaine use disorder: Comprehensive examination of money, cocaine, and health outcomes using gains and losses at multiple magnitudes. *Exp Clin Psychopharmacol*. 2020;28(6):724-38.
111. Davis AK, Clifton JM, Weaver EG, Hurwitz ES, **Johnson MW**, Griffiths RR. Survey of entity encounter experiences occasioned by inhaled N,N-dimethyltryptamine (DMT): Phenomenology, interpretation, and enduring effects. *J Psychopharmacol*. 2020;34(9):1008-20.
112. Dolan SB, **Johnson MW**. The drug purity discounting task: Ecstasy use likelihood is reduced by probabilistic impurity according to harmfulness of adulterants. *Drug Alcohol Depend*. 2020;208:107772.
113. Dolan SB, Johnson PS, **Johnson MW**. The Hotel Room Purchase Task: Effects of gender and partner-desirability on demand for hypothetical sex in individuals with disordered cocaine use and controls. *Arch Sex Behav*. 2020;49(4):1251-62.
114. Jennings Mayo-Wilson L, Glass NE, Labrique A, Davoust M, Ssewamala F, Linnemayr S, **Johnson MW**. Feasibility of assessing economic and sexual risk behaviors using text message surveys in African-American young adults experiencing homelessness and unemployment: a single-group study. *JMIR Form Res*. 2020;4(7):e14833.
115. Mayo-Wilson LJ, Coleman J, Timbo F, Glass NE, Ssewamala FM, Linnemayr S, Yi GT, Kang B, **Johnson MW**, Yenokyan G, Dodge B, Glass NE. Microenterprise intervention to reduce sexual risk behaviors and increase employment and HIV preventive practices among economically-vulnerable African-American young adults (EMERGE): a feasibility randomized clinical trial. *AIDS Behav*. 2020;24(12):3545-61.
116. Müller F, **Johnson MW**, Borgwardt S. Hallucinogens and Entactogens: Establishing a New Class of Psychotherapeutic Drugs? *Frontiers in Psychiatry*. 2020;11:497.
117. Strickland JC, Garcia-Romeu A, **Johnson MW**. Set and Setting: A Randomized Study of Different Musical Genres in Supporting Psychedelic Therapy. *ACS Pharmacology & Translational Science*. 2020;4(2):472-478.
118. Berry MS, Sweeney MM, Dolan SB, Johnson PS, Pennybaker SJ, Rosch KS, **Johnson MW**. Attention-Deficit/Hyperactivity Disorder symptoms are associated with greater delay discounting of condom-protected sex and money. *Arch Sex Behav*. 2021;50(1):191-204.
119. Cox DJ, Garcia-Romeu A, **Johnson MW**. Predicting changes in substance use following psychedelic experiences: natural language processing of psychedelic session narratives. *Am J Drug Alcohol Abuse*. 2021;47(4):444-54.
120. Davis AK, Barrett FS, May DG, Cosimano MP, Sepeda ND, **Johnson MW**, Finan PH, Griffiths RR. Effects of psilocybin-assisted therapy for major depressive disorder: A randomized clinical trial. *JAMA Psychiatry*. 2021;78(5):481-489.
121. Dolan SB, **Johnson MW**, Dunn KE, Huhn AS. The discounting of death: Probability discounting of heroin use by fatal overdose likelihood and drug purity. *Exp Clin Psychopharmacol*. 2021;29(3):219-28.
122. Garcia-Romeu A, Barrett FS, Carbonaro TM, **Johnson MW**, Griffiths RR. Optimal dosing for psilocybin pharmacotherapy: Considering weight-adjusted and fixed dosing approaches. *J of Psychopharmacol*. 2021;35(4):353-361.
123. **Johnson MW**. Consciousness, religion, and gurus: Pitfalls of psychedelic medicine. *ACS Pharmacology & Translational Science*. 2020;4(2):578-81.
124. Lochtenberg J, Kirshenbaum A, **Johnson MW**. Pharmacological assistance for psychotherapy. *Emerging Trends in Drugs, Addictions, and Health*. 2021;100017.
125. Nayak S, **Johnson MW**. Psychedelics and Psychotherapy. *Pharmacopsychiatry*. 2021;54(4):167-175.
126. Strickland JC, **Johnson MW**. Rejecting impulsivity as a psychological construct: A theoretical, empirical, and sociocultural argument. *Psychol Rev*. 2021;128(2):336-61.
127. Yaden DB, **Johnson MW**, Griffiths RR, Doss M, Garcia-Romeu A, Nayak S, Gukasayan N, Mathur BN, Barrett FS. Psychedelics and Consciousness: Distinctions, Demarcations, and Opportunities. *Int J Neuropsychopharmacol*. 2021;24(8):615-23.

128. Berry MS, Bruner NR, Herrmann ES, Johnson PS, **Johnson MW**. Methamphetamine administration dose effects on sexual desire, sexual decision making, and delay discounting. *Exp Clin Psychopharmacol*. In Press.
129. Cox DJ, **Johnson MW**. Verbal behavior related to drug reinforcement in polysubstance cannabis users: Comparison across drugs. *Exp Clin Psychopharmacol*. In Press.
130. Dolan SB, Spindle TR, Vandrey R, **Johnson MW**. Behavioral economic interactions between cannabis and alcohol purchasing: Associations with disordered use. *Exp Clin Psychopharmacol*. In Press.
131. Ermakova AO, Dunbar F, Rucker J, **Johnson MW**. A Narrative Synthesis of Research with 5-MeO-DMT. *J Psychopharmacol*. In Press.
132. Harsin JD, Gelino BW, Strickland JC, **Johnson MW**, Berry MS, Reed DD. Behavioral economics and safe sex: Examining condom use decisions from a reinforcer pathology framework. *J Exp Anal Behav*. In Press.
133. **Johnson MW**, Strickland JC, Herrmann ES, Dolan SB, Cox DJ, Berry MS. Sexual discounting: A systematic review of discounting processes and sexual behavior. *Exp Clin Psychopharmacol*. In Press
134. Naudé GP, Reed DD, Jarmolowicz DP, Martin LE, Fox AT, Strickland JC, and **Johnson MW**. Single and cross-commodity discounting among adults who use alcohol and cannabis: associations with tobacco use and clinical indicators. *Exp Clin Psychopharmacol*. In Press.
135. **Strickland JC**, Lee DC, Vandrey R, **Johnson MW**. A systematic review and meta-analysis of delay discounting and cannabis use. *Exp Clin Psychopharmacol*. In Press.
136. Teixeira PJ, **Johnson MW**, Timmermann C, Watts R, Erritzoe D, Douglass H, Kettner H, Carhart-Harris RL. Psychedelics and Health Behavior Change. *J Psychopharmacol*. In Press.
137. Yaden DV, Berghella AP, Regier PS, Garcia-Romeu A, **Johnson MW**, Hendricks PS. Classic psychedelics in the treatment of substance use disorder: Potential synergies with twelve-step programs. *Int J Drug Policy*. In Press.
138. Koslowski M, **Johnson MW**, Gründer G, Betzler. Novel treatment approaches for substance use disorders: Therapeutic use of psychedelics and the role of psychotherapy. *Curr Addict Rep*. In Press.
139. Strickland JC, Reed DD, Hursh SR, Schwartz LP, Foster RN, Gelino BW, LeComte RS, Oda FS, Salzer AR, Schneider TD, Dayton L, Latkin C, **Johnson MW**. Behavioral economic methods to inform infectious disease response: Prevention, testing, and vaccination in the COVID-19 pandemic. *PLOS ONE*. In Press.

#### Book Chapters, Monographs

1. Bickel WK, **Johnson MW**. Delay discounting: A fundamental behavioral process of drug dependence. In: Loewenstein G, Read D, Baumeister RF, eds. *Time and Decision*. New York: Russell Sage Foundation; 2003:419-40.
2. Bickel WK, **Johnson MW**. Junk time: Pathological behavior as the interaction of evolutionary and cultural forces. In: Vuchinich R, Heather N, eds. *Choice, Behavioral Economics, and Addiction*. Boston: Pergamon; 2003:249-71.
3. Bickel WK, **Johnson MW**. The continuum of discounting: A reply to comments by Keith Humphrey. In: Vuchinich R, Heather N, eds. *Choice, Behavioral Economics, and Addiction*. Boston: Pergamon; 2003:276-8.
4. Bickel WK, **Johnson MW**. Reply to Humphreys. In: Vuchinich R, Heather N, eds. *Choice, Behavioral Economics, and Addiction*. Boston: Pergamon; 2003:277-8.
5. Mintzer MZ, **Johnson MW**. Opioids. In: Kalechstein A, Van Gorp W, eds. *The Neuropsychological Consequences of Substance Abuse*. New York: Taylor Francis 2007:263-319.
6. **Johnson MW**. Cocaine. In: Kleiman M, Hawdon J, Golson JG, eds. *Encyclopedia of Drug Policy*. vol 1. Thousand Oaks, CA: Sage Publications; 2011;137-9.
7. **Johnson MW**. Rational addiction model of drug use. In: Kleiman M, Hawdon J, Golson JG, eds. *Encyclopedia of Drug Policy*. vol 2. Thousand Oaks, CA: Sage Publications; 2011;679-80.
8. **Johnson MW**. *Salvia divinorum*. In: Kleiman M, Hawdon J, Golson JG, eds. *Encyclopedia of Drug Policy*. vol 2. Thousand Oaks, CA: Sage Publications; 2011;709-11.
9. **Johnson MW**. Tobacco. In: Kleiman M, Hawdon J, Golson JG, eds. *Encyclopedia of Drug Policy*. vol 2. Thousand Oaks, CA: Sage Publications; 2011;776-9.
10. **Johnson MW**. Hallucinogens. In: Rippe JM, ed. *Encyclopedia of Lifestyle Medicine and Health*. vol 1. Thousand Oaks, CA: Sage Publications; 2012;529-30.
11. **Johnson MW**. Narcotics, Opiates, and Opioids. In: Rippe JM, ed. *Encyclopedia of Lifestyle Medicine and Health*. vol 2. Thousand Oaks, CA: Sage Publications; 2012;741-2.
12. MacLean KA, **Johnson MW**, Griffiths RR. Hallucinogens and club drugs. In: Galanter M, Kleber H, Brady K, eds. *Textbook on Substance Abuse Treatment*. 5<sup>th</sup> ed. Washington, DC: American Psychiatric Publishing; 2015;209-22.
13. Sessa B, **Johnson MW**. From addiction to recovery using altered states of consciousness. In: Dickins R., ed. *Psychedelic Press UK Volume 1*; Cornwall, UK: Psychedelic Press; 2015;71-80.
14. **Herrmann ES**, **Johnson PS**, **Johnson MW**, Vandrey R. Novel drugs of abuse: Cannabinoids, stimulants, hallucinogens. In: Preedy V, ed. *The Neuropathology of Drug Addictions and Substance Misuse*. Cambridge, MA: Academic Press, 2016;893-902.

15. **Johnson MW**. Psychedelics in the treatment of addiction. In: Grob CS, ed. Handbook of Medical Hallucinogens. New York, NY: Guilford Press; 2021;493-500.
16. Strickland JC, **Johnson MW**. Human behavioral pharmacology of psychedelics. In: Li JX, ed. Advances in Pharmacology; In Press

## FUNDING

### EXTRAMURAL Funding

#### Research Extramural Funding

##### Current

- |                  |  |
|------------------|--|
| 9/1/19-8/31/22   | <p>Greenwashing Cigarettes: Perceptual and Behavioral Evidence of Inaccurate Modified Risk Advertising<br/>R01 DA049814-01A1<br/>NIH/NIDA<br/>\$900,000<br/>Principal Investigators: Matthew W. Johnson, 36% effort (Multiple PI with Meghan Moran, Ph.D.)<br/>In collaboration with investigators at The Johns Hopkins Bloomberg School of Public Health, this research will identify tactics in cigarette ads that may inaccurately convey modified risk using our existing content analysis platform, test the effect of these tactics on risk perceptions in an online experiment, and then test the effects of these tactics on laboratory smoking self-administration using behavioral economic methods.</p> |
| 5/9/11-12/31/21  | <p>Smoking cessation with 5-HT<sub>2A</sub> agonist psilocybin and cognitive behavioral therapy<br/>Heffter Research Institute<br/>\$430,000<br/>Role: Principal Investigator; 2% effort. Nonprofit organization; This grant has supported a pilot study examining the safety and feasibility of psilocybin in smoking cessation when combined with cognitive behavioral therapy. The grant is now supporting a comparative efficacy trial comparing psilocybin to nicotine replacement therapy, both accompanied by cognitive behavioral therapy, for smoking cessation.</p>  |
| 12/1/13–12/31/21 | <p>Effects of Psilocybin on Behavior, Psychology and Brain Function in Long-Term Meditators<br/>Heffter Research Institute<br/>\$791,365<br/>Principal Investigator: Roland Griffiths<br/>Role: Co-investigator; 1% effort. This study is investigating acute and persisting effects of psilocybin on psychological functioning, spirituality, health, well-being, pro-social attitudes, behaviors, and brain function as assessed using functional magnetic resonance imaging at 3T.</p>  |
| 1/1/15-12/31/21  | <p>Incentives for Suppression of HIV-1 RNA in People Living with HIV<br/>R01 AI117065<br/>NIH/ NIAID<br/>\$2,492,776<br/>Principal Investigator: Kenneth Silverman<br/>Role: Co-investigator; 2% effort. This project is developing and evaluating a novel incentive intervention to promote suppression of viral load in people living with HIV that will employ empirically-based parameters that have been proven critical to the effectiveness of incentive interventions.</p>   |
| 9/1/16-6/30/22   | <p>Dose effects of nicotine: Behavioral economics of cigarette abuse liability<br/>R01DA042527<br/>NIH/NIDA<br/>\$1,356,425<br/>Role: Principal Investigator; 15% effort. This project is using behavioral economic assessments to determine the effects of nicotine dose on the abuse liability of tobacco cigarettes.</p>  |

11/1/18-12/31/21	<p>The Turnbull Psychedelics Studies Grant  The Turnbull Family Foundation, Inc.  \$102,000  Principal Investigator: Roland R. Griffiths  Role: Co-Investigator; 1% effort. This is an ongoing research project at the Behavioral Pharmacology Research Unit on the psychological and behavioral effects of psilocybin.</p>
7/1/19-6/30/24	<p>The Johns Hopkins Center for Psychedelic &amp; Consciousness Research  Steven and Alexandra Cohen Foundation  \$7,817,431  Role: Principle Investigator on two clinical trials, and Associate Center Director; 45% effort. The Psychedelic Research and Treatment Center at Johns Hopkins is conducting numerous studies with psychedelic compounds, including both basic behavioral and neuroscientific studies in healthy volunteers, and studies examining psychedelics as therapeutics for multiple disorders.</p>
7/1/19-6/30/24	<p>The Johns Hopkins Center for Psychedelic &amp; Consciousness Research  Tim Ferriss Collaborative  \$7,817,431  Role: Principle Investigator on two clinical trials, and Associate Center Director; 45% effort. The Psychedelic Research and Treatment Center at Johns Hopkins is conducting numerous studies with psychedelic compounds, including both basic behavioral and neuroscientific studies in healthy volunteers, and studies examining psychedelics as therapeutics for multiple disorders.</p>
<u>Previous</u>	
7/1/84-2/28/19	<p>Clinical Pharmacology/Mechanisms of Action of Emerging Abused Drugs (Club Drugs)  R01 DA003889  NIH/NIDA  \$1,871,484  Principal Investigator: Roland Griffiths  Role: Co-investigator; 4% effort. This project is examining the comparative behavioral pharmacology of hallucinogenic and related compounds to inform mechanism of action.</p>
8/11/00-12/31/20	<p>Pharmacology of Psilocybin  Council on Spiritual Practices  \$764,434  Principal Investigator: Roland Griffiths  Role: Co-investigator; 1% effort. This grant provides supplemental support for studies investigating the effect of psilocybin in healthy volunteers.</p>
1/1/05-12/31/16	<p>Psychopharmacology of Psilocybin in Cancer Patients  Heffter Research Institute  \$1,175,719  Principal Investigator: Roland Griffiths  Role: Co-investigator; 1% effort. This project examined the effects of psilocybin in a randomized controlled clinical trial treatment cancer-related anxiety and depression.</p>
4/1/09-3/31/10	<p>Development of a novel trial-by-trial consequence human delay discounting task  R03 DA026523  \$50,000  Role: Principal Investigator; 25% effort. This project supported the development of a novel assessment of delay discounting of money in cocaine dependent and non-cocaine-using participants, without several shortcomings of previous tasks.</p>
5/22/09-4/30/13	<p>Effects of Psilocybin and Spiritual Practices on Persisting Changes in Attitudes and Behavior  Fetzer, Institute  \$117,306  Principal Investigator: Roland Griffiths</p>

Role: Co-investigator; 5% effort. This grant provides support for a clinical trial investigating the effects of psilocybin on the initiation of meditation and spiritual awareness practices and on sustained changes in moods and attitudes.

- 6/1/09-5/31/12 Sexual HIV risk behavior and impulsive decision making in cocaine dependence  
R21 DA026967  
NIH/NIDA  
\$275,000  
Role: Principal Investigator; 25% effort. This project investigated the behavioral mechanisms responsible for the high rates of sexually transmitted HIV in cocaine dependent individuals. In this project I developed the sexual discounting task which is the focus of subsequent grant applications examining acute drug effects on sexual risk behavior and delay discounting.
- 5/1/11-4/30/13 Pharmacotherapy for cocaine dependence: d-cycloserine with contingency management  
R21 DA029823  
NIH/NIDA  
\$275,000  
Role: Principal Investigator; 25% effort. This project examined the efficacy of learning enhancer and NMDA partial agonist d-cycloserine in facilitating contingency management treatment for cocaine dependence.
- 4/1/12–2/28/15 HIV sexual risk behavior: methamphetamine and delay discounting of sexual rewards  
R21 DA032717  
NIH/NIDA  
\$250,000  
Role: Principal Investigator; 20% effort. This grant examines the acute effects of methamphetamine on delay discounting and measures of HIV risk, including the delay discounting of sexual HIV risk behavior, in stimulant abusing individuals.
- 8/1/12-6/30/16 Role of delay discounting in driving HIV sexual risk behavior in cocaine abuse  
R01DA032363  
NIH/NIDA  
\$592,000  
Role: Principal Investigator; 15% effort. This project has compared cocaine dependent and non-cocaine-using participants on delay discounting and its role in sexual risk behavior. It is also determining the acute effects of cocaine administration on these outcomes.
- 6/1/13-5/31/16 Cognitive training in adolescents during treatment for substance use disorders  
R21DA034942  
NIH/NIDA  
\$292,674  
Role: Principal Investigator; 9.5% effort. This project is determining the effects of a working memory training course on drug abuse and delay discounting outcomes among adolescents in a community drug treatment program.
- 9/16/13-6/30/19 Development of a prospective memory intervention to reduce drug use and HIV risk  
R01DA035277  
NIH/NIDA  
\$1,579,762  
Role: Principal Investigator; 33% effort. This project is developing a program for training prospective memory in substance use disorder treatment clinic patients, and will determine its effects on delay discounting and HIV risk behavior.
- 9/15/14-5/31/21 A118G SNP and OPRM1 Gene Opioid-Mediated Effects in Humans  
R01 DA035246  
NIH/NIDA  
\$1,984,305  
Principal Investigator: Kelly Dunn

Role: Co-investigator, 5% effort. This project examines genetic contributions to the nature of opioid effects including abuse potential in humans.

- 7/1/15-6/30/16 Psilocybin-Facilitated Smoking Cessation Treatment: A Pilot Study  
Beckley Foundation  
\$20,000  
Role: Principal Investigator; 2% effort. Nonprofit organization; This grant provides supplement support for a randomized trial assessing 5-HT2A agonist psilocybin in smoking cessation.
- 9/1/15-8/31/17 Neural Correlates of Impulsive Risky Sex: Decision-Making Among Stimulant Users  
R21 DA040559  
NIH/NIDA  
\$21,711  
Principal Investigator: Mikhail Koffarnus  
Role: Co-investigator; 7% effort. This project, conducted by the Principal Investigator at Virginia Tech, is using fMRI to determine the biological correlates of sexual risk behavior among stimulant users.
- 9/30/15-8/31/18 Effects of Oxytocin on the Human Abuse Liability of Methamphetamine  
R21 DA036675  
NIH/NIDA  
\$275,000  
Role: Principal Investigator; 15% effort. This project is determining the effect of intranasal oxytocin on the abuse liability of methamphetamine.
- 8/1/19-11/30/19 Protocol Development: Holotropic Breathwork in Treating Veterans with Post Traumatic Stress Disorder  
Psykia Institute  
\$13,545  
Role: Principal Investigator; 4.7% effort. This project is for the development of a protocol examining breathwork in the treatment of posttraumatic stress disorder (PTSD).
- 8/1/19-8/15/20 A Randomized, Double-Blind, Support-of-Concept Phase 2 Study of Single-Dose Psilocybin for Major Depressive Disorder  
Usona Institute  
\$531,290  
Principal Investigator: Roland R. Griffiths  
Role: Co-Investigator; 10% effort. This is a multi-site, randomized, double-blind, clinical trial evaluating the potential efficacy of a single 25 mg oral dose of psilocybin for Major Depressive Disorder (MDD) compared to an active placebo in otherwise medically-healthy participants between the ages of 18 and 65.

Educational Extramural Funding – Grants or contracts obtained to support an educational initiative, incl. training grants

- 7/1/16-6/30/21 Human Behavioral Pharmacology of Substance Abuse  
T32 DA007209  
NIH/NIDA  
\$2,728,932  
Principal Investigator: George Bigelow  
Role: Faculty Mentor; This grant supports the training of postdoctoral fellows in human behavioral pharmacology. I have served as faculty mentor for several postdoctoral fellows on this training grant.

Other Extramural Funding, including philanthropy                      None

**INTRAMURAL Funding**                      None

**CLINICAL ACTIVITIES** Not applicable; non-clinical degree.

## **EDUCATIONAL ACTIVITIES**

### **Educational Focus**

My educational focus is the scientific mentorship of postdoctoral fellows and junior faculty members. Mentored activities have included experimental design, study conduct, data analysis, peer-reviewed manuscript writing and publication, and grant writing.

### **Teaching**

#### **Classroom instruction**

- 1997-1998 Role: Psychology Department Teaching Assistant; Learner level: Undergraduate; Course title: multiple courses within Department of Psychology, Eastern Oregon University; Explanatory notes: Responsible for paper grading, test scoring, grade entry, and laboratory animal care
- 1997-1998 Role: Supplemental Instructor; Learner level: Undergraduate; Course title: General Psychology, Department of Psychology, Eastern Oregon University; Explanatory notes: Responsible for paper grading, test scoring, grade entry
- 2001-2002 Role: Instructor; Learner level: Undergraduate; Course title: General Psychology, Department of Psychology, University of Vermont; Explanatory notes: Responsible for all aspects of course
- 2002 Role: Instructor; Learner level: Undergraduate; Course title: Psychology of Learning, Department of Psychology, St. Michael's College; Explanatory notes: Responsible for all aspects of course
- 2002 Role: Instructor; Learner level: Undergraduate; Course title: Psychopharmacology, Department of Psychology, University of Vermont; Explanatory notes: Responsible for all aspects of course
- 2002-2003 Role: Guest lecturer; Learner level: Medical students; Course title: Human Behavioral Pharmacology, College of Medicine, University of Vermont; Explanatory notes: Taught section on Behavior Analysis and Pharmacology
- 2008 Role: Guest lecturer; Learner level: Masters in Public Health students; Course title: Current Issues in Public Health, John Hopkins Bloomberg School of Public Health, Johns Hopkins University; Explanatory notes: Lectured on public health aspects of hallucinogens
- 2012 Role: Guest lecturer, Learner level: Graduate (PhD) students; Course: Drugs and Behavior, Department of Applied Developmental Psychology, University of Maryland Baltimore County; Explanatory notes: Lectured on the pharmacology of hallucinogens
- 2012-2015 Role: Guest lecturer; Learner level: Masters of Arts in Science Writing students; Course title: Science Journalism, Johns Hopkins University School of Arts and Sciences, Johns Hopkins University; Explanatory notes: Lectured on my research studies that have been the subject of media reports

#### **Workshops /seminars**

##### **National**

- 2015 Role: Chair, presenter; Learning level: Professional scientists; Course title: The case for rescheduling psilocybin as a treatment medications: Regulatory rationale, abuse liability, safety, and treatment efficacy; College on Problems of Drug Dependence, Phoenix, AZ.

### **Mentoring**

#### **Post-doctoral Advisees /Mentees**

- 2010 – 2013 Natalie R. Bruner, Ph.D., Present position: Science Writer for Hayes Inc.; Awards: 2010 National Institute on Drug Abuse Director's Travel Award for attending the College on Problems of Drug Dependence; 2011 NIH Loan Repayment Program; 2012 National Institute on Drug Abuse Women & Sex/Gender Junior Investigator Travel Award for attending the College on Problems of Drug Dependence
- 2012 – 2015 Patrick S. Johnson, Ph.D., Present position: Assistant Professor, Department of Psychology, California State University, Chico; Awards: 2013 National Institutes of Health Clinical Loan Repayment Program; 2015 College of Behavioral and Social Sciences Strategic Performance Fund Award, California State University, Chico; 2015 College of Behavioral and Social Sciences Faculty Travel Fund, California State University, Chico; 2016 Professor of the Month (March), Department of Psychology, California State University, Chico; 2018 Brady Award from the Journal of Experimental Analysis of Behavior
- 2012 – 2015 Albert P. Garcia-Romeu, Ph.D., Present position: Research Associate in Department of Psychiatry and Behavioral Sciences; Awards: 2014 American Psychological Association Interdivisional Mentoring Award; 2014 National Institute on Drug Abuse Director's Travel Award for attending the College on Problems

- of Drug Dependence; 2018 Journal of Psychopharmacology Prize from the Journal of Psychopharmacology; 2018 National Institutes of Health Clinical Loan Repayment
- 2013 – 2015 Evan S. Herrmann, Ph.D.; Present position: Postdoctoral fellowship at Columbia University; Award: 2018 Brady Award from the Journal of Experimental Analysis of Behavior
- 2013 – 2015 Olga Rass, Ph.D.; Present position: Scientist at Food and Drug Administration, Center for Tobacco Products; Award: 2015 National Institute on Drug Abuse Director’s Travel Award for attending the College on Problems of Drug Dependence
- 2014- 2017 Mary M. Sweeney, Ph.D., Present position: Instructor in Department of Psychiatry and Behavioral Sciences; Awards: 2016 National Institute on Drug Abuse Director’s Travel Award for attending the College on Problems of Drug Dependence; 2016 NIH Loan Repayment Program
- 2015 – 2018 Meredith S. Berry, Ph.D.; Present position: Assistant Professor, Department of Health Education and Behavior, University of Florida; Award: 2018 National Institute on Drug Abuse Director’s Travel Award for attending the College on Problems of Drug Dependence Director annual conference
- 2017 – Present Sean Dolan, Ph.D.; Present position: Currently in postdoctoral fellowship; Awards: 2019 American Psychological Association Division 28 finalist and American Psychological Association semifinalist at “Science at Sundown” poster competition at the 2019 American Psychological Association Annual Convention; 2019 National Institute on Alcohol Abuse and Alcoholism Early Career Travel Award for attending American Psychological Association annual convention; 2019 William L. Woolverton Travel award recipient for International Study Group Investigating Drugs as Reinforcers annual meeting
- 2018 – Present David Cox, Ph.D.; Present position: Currently in postdoctoral fellowship; Award: 2019 National Institute on Alcohol Abuse and Alcoholism Early Career Travel Award for attending American Psychological Association annual convention
- 2019 – Present Justin Strickland, Ph.D; Present position: Currently in postdoctoral fellowship

#### Thesis committees

- June 2020 Swasti Mishra, Dissertation for Ph.D.: “Clinical studies on psychedelic assisted psychotherapy”, Dissertation Jury Member; Travel to Dissertation Defense provided by the University of Amsterdam.

## RESEARCH ACTIVITIES

### Research Focus

#### Delay discounting

- Developed/validated widely-used methods
- Connected delay discounting and addiction
- Pioneered discounting in sexual risk

#### Behavioral economics in tobacco regulation

- Tobacco/nicotine demand
- Current research determining demand for reduced-nicotine cigarettes

#### Novel Psychoactives

- Developed psilocybin as smoking cessation medication
- Current RCT and fMRI of psilocybin in smoking cessation

## ORGANIZATIONAL ACTIVITIES

### Institutional Administrative Appointments

- 2010 – Present Behavioral Pharmacology Research Unit Executive Committee, approximately 1 hour/week
- 2013 – 2016 Behavioral Pharmacology Research Unit Director Search Committee

### Editorial Activities

- 2017 Guest Editor, International Review of Psychiatry; Issue: The renaissance in psychedelic research; published in 2018
- 2019 Guest Editor, Frontiers in Psychiatry; Issue: Hallucinogens and entactogens: Establishing a new class of psychotherapeutic drugs?; Published in 2020

### Editorial Board appointments

- 2014-2016 Editorial Board Member, Journal of the Experimental Analysis of Behavior
- 2017 Inaugural Editorial Board Member, Journal of Psychedelic Studies



2017-2021 Editorial Board Member, Experimental and Clinical Psychopharmacology

#### Journal peer review activities

2014-2018 Addiction  
2012-2013 Addiction Biology  
2011 Addiction Research and Theory  
2015 Addictive Behaviors  
2014-2015 Alcoholism: Clinical and Experimental Research  
2014-2015 American Journal of Addictions  
2010-2015 American Journal of Drug and Alcohol Abuse  
2004 American Journal of Psychiatric Rehabilitation  
2015-2017 Archives of Sexual Behavior  
2012 Behavior Analyst Today  
2015 Behavior Research Methods  
2006 Behavioural Pharmacology  
2011-2017 Behavioral Processes  
2013-2015 Biological Psychiatry  
2016-2020 British Journal of Psychiatry  
2020 Cell  
2014 Clinical Medicine Insights: Women's Health  
2005-2009 CNS Drugs  
2014 Current Drug Abuse Reviews  
2016 Current Opinion in Behavioral Sciences  
2004-2017 Drug and Alcohol Dependence  
2010-2012 Drug Testing and Analysis  
2015 Dual Diagnosis: Open Access  
2016 European Psychiatry  
2005-2019 Experimental and Clinical Psychopharmacology  
2016 FASEB (Federation of American Societies for Experimental Biology) Journal  
2016 Frontiers in Human Neuroscience  
2016 Human Brain Mapping  
2015 International Archives of Addiction Research and Medicine  
2015 Journal for the Scientific Study of Religion  
2013-2014 Journal of Abnormal Psychology  
2014 Journal of Addiction Medicine  
2019 Journal of Affective Disorders  
2006-2014 Journal of Applied Behavior Analysis  
2014 Journal of Clinical Psychopharmacology  
2016 Journal of Drug Abuse  
2004 Journal of Experimental Psychology: General  
2010-2011 Journal of Experimental Psychology: Learning, Memory, and Cognition  
2019 Journal of Humanistic Psychology  
2014 Journal of Medicinal Plant Research  
2015 Journal of Nervous and Mental Disease  
2014 Journal of Neuroinfectious Diseases  
2009 Journal of Neuroscience, Psychology, and Economics  
2007-2014 Journal of Pharmacology and Experimental Therapeutics  
2010-2019 Journal of Psychopharmacology  
2013 Journal of Studies on Alcohol and Drugs  
2010-2012 Journal of Substance Abuse Treatment  
2011-2016 Journal of the Experimental Analysis of Behavior  
2015 Journal of Visualized Experiments (JoVE)  
2015 Lancet Psychiatry  
2016 Molecular Psychiatry  
2019 Nature Reviews Neuroscience  
2010-2014 Nicotine and Tobacco Research  
2015 Neuroscience of Consciousness

2011-2013	Pharmacology, Biochemistry and Behavior
2014	PLoS Biology
2012-2014	PLoS ONE
2014	Preventive Medicine
2018	Proceedings of the National Academy of Sciences (PNAS)
2015	Psychiatry Research
2009	Psychiatry (Edgemont)
2012-2013	Psychology of Addictive Behaviors
2015	Psychological Medicine
2012-2017	Psychological Record
2014	Psychological Reports
2006	Psychonomic Bulletin and Review
2011-2019	Psychopharmacology
2016	Scientific Reports
2014	SciTechnol
2012	Schizophrenia Research
2012	Sociological Inquiry
2016	SpringerPlus
2015	Substance Abuse
2015	Substance Use and Misuse
2015	The Behavior Analyst
2015	The Journal of General Psychology
2015	Translational Issues in Psychological Science

Other peer review activities      None

#### Advisory Committees, Review Groups/Study Sections

##### U.S. Military

9/10	Grant reviewer, US Army Medical Research and Materiel Command (USAMRMC), American Institute of Biological Sciences (AIBS), Congressionally Directed Medical Research Programs, Peer Reviewed Medical Research Program 2010: Drug Abuse.
4/16	Expert reviewer for military health care provider guidance: Ayahuasca for the Treatment of PTSD; Defense Centers of Excellence for Psychological Health and Traumatic Brain Injury (DCoE); Defense Health Agency (DHA), Healthcare Operations Directorate, Military Health System

##### National Science Foundation (NSF)

3/14	Grant reviewer, National Science Foundation: National Decision, Risk, and Management Sciences Program.
10/17	Grant reviewer, National Science Foundation: National Decision, Risk, and Management Sciences Program.

##### Foreign Governments/Agencies

12/13	Grant reviewer, Netherlands Organisation for Scientific Research (NWO) Council for the Social Sciences (MaGW). Grant Review of Innovative Research Incentives Scheme (Vidi).
3/16	Grant reviewer, South African Medical Research Council (MRC). Brain, Mental Health Disorders. Self-initiated Research (SIR) Grant Review.
4/19	Dutch Organisation for Health Research and Development (ZonMw). Grant Reviewer for Rational Pharmacotherapy Program.

##### National Institutes of Health (NIH)

3/10	Grant reviewer, National Institute on Drug Abuse (NIDA) Special Emphasis Panel ZDA1 GXM -A(02) Behavioral Science Track Award for Rapid Transition (B/START) R03 Review Group.
1/11	Grant reviewer, National Institute on Drug Abuse (NIDA) Special Emphasis Panel ZRG1 BBBP-T (03), member conflict panel for Biobehavioral Regulation, Learning, and Ethology (BRLE) study section.
5/11	Grant reviewer, National Institute on Dental and Craniofacial Research (NIDCR) Special Emphasis Panel for RFA-DE-12-001: NIDCR Behavioral or Social Intervention Planning and Pilot Data Grant (R34).

- 10/11 Grant reviewer, National Institute on Drug Abuse (NIDA) Special Emphasis Panel ZRG1 BBBP-J 04 M, member conflict panel for Biobehavioral Regulation, Learning, and Ethology (BRLE) study section.
- 3/12 Grant reviewer, National Institute on Drug Abuse (NIDA) Special Emphasis Panel ZRG1 EMNR-Q (50) OD-11-003: Specialized Centers of Research (SCOR) on Sex Differences (P50).
- 4/12 Grant reviewer, National Institute on Drug Abuse (NIDA) Special Emphasis Panel/Scientific Review Group 2012/08 ZRG1 BBBP-R (51) R, Basic Research on Decision Making: Cognitive, Affective, and Developmental Perspectives (R01) Funding Opportunity Announcement (FOA).
- 11/13 Grant reviewer, National Institute on Drug Abuse (NIDA) Special Emphasis Panel/Scientific Review Group 2014/01 ZRG1 BBBP-X (03) M, Member Conflict: Biobehavioral Regulation, Learning and Ethology.
- 3/14 Grant reviewer, National Institute on Drug Abuse (NIDA) Special Emphasis Panel/Scientific Review Group 2014/05 ZRG1 F16-L (20) L. Review of F31, F32, and R36 applications.
- 7/14 Grant reviewer, National Institute on Drug Abuse (NIDA) Special Emphasis Panel/Scientific Review Group 2014/05 ZRG1 F16-L (20) L. Review of F31, F32, and R36 applications.
- 7/14 Grant reviewer, National Institute on Drug Abuse (NIDA) Special Emphasis Panel/Scientific Review Group 2014/10 ZRG1 F16-M (02) S. Review of F31, F32, and R36 applications.
- 7/14 Grant reviewer, National Institute on Drug Abuse (NIDA) Special Emphasis Panel/Scientific Review Group 2014/01 ZRG1 BBBP-X (03) M, Member Conflict: Biobehavioral Regulation, Learning and Ethology.
- 7/14 Grant reviewer, National Institute on Aging (NIA), Roybal Centers for Translational Research on Aging (P30) 2014/08 ZAG1 ZIJ-9 (A1).
- 11/14 Grant reviewer, National Institute on Drug Abuse (NIDA) Special Emphasis Panel/Scientific Review Group 2014/05 ZRG1 F16-L (20) L. Review of F31, F32, and R36 applications.
- 7/15 Grant reviewer, National Institute on Drug Abuse (NIDA) Special Emphasis Panel/Scientific Review Group 2015/10 ZRG1 BBBP-T (02) M, member conflict panel for Biobehavioral Regulation, Learning, and Ethology (BRLE) study section.
- 7/16 Grant reviewer, National Institute on Drug Abuse (NIDA) Special Emphasis Panel/Scientific Review Group 2016/10 ZRG1-F16-L-20, Review of F31, F32, and R36 applications.
- 7/16 Grant reviewer, National Institute on Drug Abuse (NIDA) Special Emphasis Panel/Scientific Review Group 2016/10 ZRG1-F16-M-07, Review of F31, F32, and R36 applications.
- 10/16 Grant reviewer, National Institute on Drug Abuse (NIDA) Addiction Risks and Mechanisms Study Section.
- 10/16 Grant reviewer, National Institute On Aging (NIA) Special Emphasis Panel/Scientific Review Group 2017/01 ZAG1 ZIJ-4 (J1), Networks and Neighborhoods.
- 6/17 Grant reviewer, National Institute on Drug Abuse (NIDA) Addiction Risks and Mechanisms Study Section.
- 6/17 Grant reviewer, National Institute on Drug Abuse (NIDA) Special Emphasis Panel/Scientific Review Group ZRG1 RPHB-N 55 R, PAR Panel: Target Assessment, Engagement and Data Replicability to Improve Substance Use Disorders Treatment Outcomes

#### Standing Study Section Membership

7/17-6/21 Standing membership in Addiction Risks and Mechanisms Study Section.

#### Professional Societies

- 1999-Present Society for Quantitative Analysis of Behavior  
1999-Present Member
- 2000-present American Psychological Association  
2000-Present Member
- 2010 Convention Program Chair for Division 28 (Psychopharmacology and Substance Abuse)
- 2012-2014 Division 28 (Psychopharmacology and Substance Abuse); Member-at-Large elected officer
- 2013 Division 28 (Psychopharmacology and Substance Abuse); Educational Leadership Conference Representative
- 2015 Programming Committee Collaborative Perspectives on Addiction, Division 50 (Addictions)
- 2016-2018 Division 28 (Psychopharmacology and Substance Abuse); Fellows Chair

	2017-2018	Division 28 (Psychopharmacology and Substance Abuse); President-Elect (elected officer). Presidential term to begin 8/2018
	2018-2019	Division 28 (Psychopharmacology and Substance Abuse); President (elected officer)
2000-present		Association for Behavior Analysis International
	2000-Present	Member
	2015-2016	Area Co-coordinator for Behavioral Pharmacology and Neuroscience
	2017-2018	Senior Area Coordinator for Behavioral Pharmacology and Neuroscience
	2017-2019	Science Board Member
2000-Present		College on Problems of Drug Dependence
	2000-Present	Member
	2007-2010	Human Research Committee Member
	2012-2015	Under-Represented Populations Committee Member
	2015-2017	Programming Committee
2004-Present		International Study Group Investigating Drugs as Reinforcers
	2004-Present	Member
2016-Present		International Society for Research on Psychedelics
	2016-Present	Member
	2016-Present	President-Elect (elected officer)
	2018-Present	Organizing and Programming Committees

### Conference Organizer

#### International

10/19	International Society for Research on Psychedelics. Founding member and seminal President-Elect for the society; drafted organization bylaws, member of organizing committee preparing for first society meeting in New Orleans, LA, scheduled for October 17-20, 2019.
-------	---

### Session Chair

#### National

2004	American Psychological Association, Honolulu, HI; Delay discounting: Exploring its association with drug dependence
2010	American Psychological Association, San Diego, CA; Psychopharmacology and public policy
2010	American Psychological Association, San Diego, CA; Therapeutic uses of hallucinogens in the treatment of psychological disorders
2010	Association for Behavior Analysis International, San Antonio, TX; Delay discounting
2011	American Psychological Association, Washington DC; Emerging drugs of abuse
2014	College on Problem of Drug Dependence, San Juan, Puerto Rico; Novel approaches to examining the intertwining epidemics of HIV and drug abuse: From decision-making to viral load
2014	American Psychological Association, Washington, DC; Cannabis, prescription drugs, and legal highs – Research on drugs of evolving or mixed legal status
2016	Association for Behavior Analysis International. Chicago, IL; BF Skinner Lecture Series; Aston-Jones G: Unraveling Brain Circuits for Drug Seeking and Demand
2016	College on Problem of Drug Dependence, Palm Springs, CA; Club drugs
2017	American Psychological Association, Washington, DC; Exploring therapeutic potential of abused drugs
2018	Association for Behavior Analysis International; San Diego, CA; Behavioral Pharmacology and Neuroscience Poster Session Chair
2018	Association for Behavior Analysis International, San Diego, CA; Behavioral Economics and Public Policy
2018	Association for Behavior Analysis International, San Diego, CA; BF Skinner Lecture Series; Carhart-Harris R: Psychedelics: Mechanisms and Therapeutic Potential
2018	College on Problem of Drug Dependence, San Diego, CA, Drug addiction treatment with classic psychedelics
2019	American Psychological Association, Chicago, IL; Thought Leader Session, Pollan M: How to Change Your Mind: The Promise of Psychedelic Therapy
2019	American Psychological Association, Chicago, IL; Deep dive conversation, Pollan M
2019	American Psychological Association, Chicago, IL; Psychedelic Therapy: A guide, a volunteer, and a discussion with author Michael Pollan

### Consultantships

- 2010 Eli Lilly and Company, Indianapolis, IN; Notes: Consultation regarding medication in development and abuse potential
- 2014 J.W. Carney, Jr. & Associates, Attorneys at Law, Boston, MA; Notes: Consultation on legal case involving drug intoxication

## RECOGNITION

### Awards, Honors

- 1998 Outstanding Psychology Student Award, Eastern Oregon University
- 2001 Graduate Student Mini-Grant Travel Award, University of Vermont
- 2002 Travel Award for the Graduate Student Workshop in Experimental Economics, George Mason University, Fairfax, VA, International Foundation for Research in Experimental Economics
- 2002 Travel Award for the College on Problems of Drug Dependence, Québec City, Québec, Canada, National Institute on Drug Abuse
- 2003 Student Paper Award, Experimental Analysis of Human Behavior Special Interest Group of the Association for Behavior Analysis
- 2003 Graduate Student Mini-Grant Travel Award, University of Vermont
- 2003 Travel Award for the American Psychological Association, Toronto, Ontario Canada, National Institute on Drug Abuse
- 2004 Student Presenter Grant for the Annual Convention of the Association for Behavior Analysis, Boston, MA, Society for the Advancement of Behavior Analysis
- 2004 Woman and Gender Differences Travel Award for the Annual Scientific Meeting of the College on Problems of Drug Dependence, San Juan, PR, National Institute on Drug Abuse
- 2006 Travel Award for the American Psychological Association, New Orleans, LA, National Institute on Drug Abuse
- 2007 Early Career Investigator Award for the College on Problems of Drug Dependence. Québec City, Québec, Canada, College on Problems of Drug Dependence
- 2008 Extramural Clinical Research Student Loan Repayment Program Award, National Institutes of Health
- 2010 Extramural Clinical Research Student Loan Repayment Program Award Competitive Renewal, National Institutes of Health
- 2011 Extramural Clinical Research Student Loan Repayment Program Award Competitive Renewal, National Institutes of Health
- 2011 Wyeth Young Psychopharmacologist Award, American Psychological Association Division 28: Substance Abuse and Psychopharmacology
- 2014 Early Career Impact Award; Federation of Associations in Behavioral & Brain Sciences, and Association for Behavior Analysis International; Notes: “Recognizes scientists who have made major contributions to the sciences of mind, brain, and behavior”
- 2016 Fellowship status; American Psychological Association; Notes: Recognizing “evidence of unusual and outstanding contribution or performance in the field of psychology”
- 2018 Brady Award, from the Journal of Experimental Analysis of Behavior, for the manuscript “Opportunity costs of reward delays and the discounting of hypothetical money and cigarettes.” This award recognizes the manuscript that received the most citations in the previous 3 years (excluding self-citations) and honors Dr. Joseph Brady and his legacy of impactful research.
- 2018 Journal of Psychopharmacology Prize, from the Journal of Psychopharmacology, for the manuscript “Pilot study of the 5-HT<sub>2A</sub>R agonist psilocybin in the treatment of tobacco addiction.” This award recognizes the manuscript that received the highest level of citations of all original research articles published in Journal of Psychopharmacology in the 2014 volume.
- 2020 Society for the Advancement of Behavior Analysis Award for Effective Presentation of Behavior Analysis in the Mass Media. Award provides hotel coverage to receive the award at the Association for Behavior Analysis International annual convention in Washington, DC.
- 2021 Appointed the Susan Hill Ward Endowed Professor of Psychedelics and Consciousness Research in the Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine.

### Invited Talks

#### JHMI/Regional

- 1/19/11 “*Salvia divinorum*: An emerging drug of abuse.” Meeting of the Maryland Association of Chemical Dependency Nurses, Baltimore, MD

- 9/9/11 “*Sabia divinorum*: A novel hallucinogenic drug of abuse.” Annual Advancement in Clinical Excellence (ACE) Seminar for Nurses, Johns Hopkins Bayview Medical Center, Baltimore, MD
- 9/26/11 “*Sabia divinorum* and other emerging drugs of abuse: A new world of legal highs.” Road to Recovery, Johns Hopkins Center for Substance Abuse Treatment and Research, Baltimore, MD
- 10/1/12 “Sexual decision making in stimulant addiction: Mechanisms underlying HIV risk.” Behavioral Pharmacology Research Unit Seminar Series, Baltimore, MD
- 10/1/15 “Choice over time: The science of delay discounting.” Johns Hopkins Science of Learning Institute, Event on Decision Making, Baltimore, MD
- 1/5/16 “Combining behavioral economics and behavioral pharmacology to understand the link between cocaine use and HIV sexual risk behavior.” Johns Hopkins Psychiatry Research Conference, Baltimore, MD
- 11/9/19 “Psilocybin treatment of depression and tobacco addiction.” The Maryland Psychiatric Society Psychopharmacology Conference, Baltimore, MD
- 12/6/19 “Psychedelics: Risks, safeguards, and potential therapeutic effects.” Featured speaker at the 14th Annual Johns Hopkins Bayview Research Symposium, Baltimore, MD
- 2/12/20 “Psychedelics and Behavior Change.” Johns Hopkins Welch Center Grand Rounds. Johns Hopkins Bloomberg School of Public Health. Baltimore, MD
- 1/7/21 “Psychedelics: Safety, Behavior Change, and Future Directions.” National Institute on Drug Abuse Intramural Research Program Clinical Rounds
- 12/4/20 “Psychedelics as Behavior Change Agents.” Maryland Association for Behavior Analysis <https://www.mdaba.org/maba-events/annual-behavioral-analysis-conference-and-workshop/presentation-abstracts-bios-materials/>

#### National

- 8/26/2007 “Recent advances in clinical research of psilocybin.” Telluride Mushroom Festival, Telluride Institute, Telluride, CO
- 4/5/08 “Delay discounting in marijuana-dependent individuals”. Virginia Association for Behavior Analysis. James Madison University, Harrisonburg, VA
- 4/8/10 “The Johns Hopkins guidelines for safely conducting human hallucinogen research.” Multidisciplinary Association for Psychedelic Studies, Psychedelic Science in the 21st Century, San Jose, CA
- 10/16/10 “Psilocybin in smoking cessation: A pilot study.” Horizons Media, Horizons: Perspectives on Psychedelics, New York, NY
- 8/4/11 “From microeconomics to mystical experience: Expanding the frame of human psychopharmacology.” Wyeth Young Psychopharmacologist Award Lecture, American Psychological Association, Washington, DC
- 10/31/11 “Human behavioral pharmacology of hallucinogens: Recent findings with psilocybin and salvinorin A.” Division on Substance Abuse at the Columbia University College of Physicians and Surgeons and the New York State Psychiatric Institute, New York, NY
- 10/15/11 “Recent findings from the Johns Hopkins hallucinogen research group.” Horizons Media, Horizons: Perspectives on Psychedelics, New York, NY
- 12/2/11 “Psilocybin as an adjunct to tobacco smoking cessation: Rationale and preliminary observations.” The New York University School of Medicine, Department of Psychiatry Division of Alcoholism and Drug Abuse, Bellevue Hospital Center, New York, NY
- 11/29/11 “*Sabia divinorum*: A novel hallucinogen.” Webinar presented to the Steering Committee, National Institutes on Drug Abuse Clinical Trials Network (CTN), Ohio Valley Node
- 3/28/2012 “Hallucinogen use and abuse.” Behavioral Health Webinar Series, Prairielands Addiction Technology Transfer Center Network (ATTC) and Wisconsin Bureau of Prevention, Treatment and Recovery (BPTR)
- 4/22/12 “Emerging Drugs: Synthetic Cannabinoids and Substituted Cathinones.” 43rd Annual Medical-Scientific Conference, American Society of Addiction Medicine (ASAM), Atlanta, GA
- 5/9/13 “Human research with the 5-HT<sub>2a</sub> agonist psilocybin.” Cruz Brain Mind & Consciousness Conference, University of California Santa, Santa Cruz, CA
- 4/20/13 “Pharmacokinetics and Phenomenology of Inhaled Salvinorin A in Humans.” Multidisciplinary Association for Psychedelic Studies, Psychedelic Science 2013, San Jose, CA
- 4/21/13 “Psilocybin-Facilitated Treatment for Addiction: Smoking Cessation.” Multidisciplinary Association for Psychedelic Studies, Psychedelic Science 2013, San Jose, CA
- 9/3/13 “Using Psilocybin to Help People to Quit Smoking – A Pilot Study.” Webinar presented to Knowledge Exchange Meeting, Clean Air Coalition of British Columbia

- 12/16/13 “Delay discounting: Innovation in understanding risk behavior.” Vermont Center on Behavior and Health (VCBH) Lecture Series, Department of Psychiatry, University of Vermont, Burlington, VT
- 3/21/14 “Delay discounting: Advances in the study of risk behavior.” Institute for Neuroscience, Texas A&M University, College Station, TX
- 10/2/14 “Delay discounting and cocaine abuse.” Addiction Research Seminar Series, Specialized Center of Research (SCOR) on Sex and Gender Factors Affecting Women's Health (P50), Medical University of South Carolina (MUSC), Charleston, SC
- 10/30/14 “Recent research on the human behavioral pharmacology of psychedelics.” Department of Psychology, University of North Carolina Wilmington, Wilmington, NC
- 11/1/14 “Sexual discounting: A vector for HIV in addiction.” Southeastern Association for Behavior Analysis (SEABA), Wilmington, NC
- 3/9/15 “Behavioral economics of e-cigarette abuse liability.” Center for Tobacco Products, Electronic Cigarettes and the Public Health: A Public Workshop, Food and Drug Administration, Hyattsville, MD
- 4/23/15 “Novel Directions in Addictions Treatment Research.” National Council on Alcoholism and Drug Dependence (NCADD), St. Louis University, St. Louis, MO
- 5/25/15 “Behavioral economics of sexual HIV risk behavior in humans: Sexual discounting.” Scientific Board Invited Lecture, Association for Behavior Analysis International (ABAI), San Antonio, TX
- 5/25/15 “Psychedelics as Adjunct Medications in Behavioral Treatments of Addiction.” Behavioral Pharmacology Invited Lecture, Association for Behavior Analysis International (ABAI), San Antonio, TX
- 3/30/15 “Psychedelics in the treatment of addiction.” Year of Health: Illicit Drugs and Health, University of Pennsylvania, Philadelphia, PA
- 8/25/15 “5-HT<sub>2A</sub> agonists in the treatment of addiction.” Grand Rounds, Department of Psychiatry, University of Alabama at Birmingham, Birmingham, AL
- 10/16/15 “Psilocybin in the treatment of addictions.” Psychedelic Medicine: The New Science of Hallucinogens, Museum of Science, Boston, MA
- 11/3/15 “Investigating Psilocybin in the treatment of addiction and cancer-related anxiety and depression.” Grand Rounds, Department of Psychiatry, University of New Mexico, Albuquerque, NM
- 3/31/16 “Recent advances in human research with psilocybin.” Perspectives in Psychedelic Medicine Meeting, Northeastern University, Boston, MA
- 3/12/16 “Combining behavioral economics and behavioral pharmacology to understand drug-related sexual risk behavior.” Department Applied Behavioral Science, University of Kansas, Lawrence, KS
- 4/11/16 “Psilocybin in the treatment of addiction and cancer-related anxiety and depression.” Department of Pharmacology and Toxicology, University at Buffalo, Buffalo, NY
- 8/4/16 “Psychopharmacology and behavioral economics of drug-related sexual risk behavior.” Division 28 (Substance Abuse and Psychopharmacology) New Fellows Address, American Psychological Association, Denver, CO
- 9/8/16 “The re-emergence of psychedelics as human research tools and therapeutics.” Columbia University Medical Center, Division on Substance Abuse, New York, NY
- 11/11/16 “The Resurgence of Psychedelics as Human Research Tools and Potential Therapeutics.” College of Psychiatric and Neurologic Pharmacists, Temple University, Philadelphia, PA
- 4/23/17 “Psychedelics as behavior change agents: Addiction recovery and beyond.” Multidisciplinary Association for Psychedelic Studies, Psychedelic Science 2017, Oakland, CA
- 4/29/17 “Emerging research on psilocybin as a potential therapeutic in addiction treatment.” Manifesting Minds Conference, Brown University, Providence, RI
- 5/29/17 “Navigating the grant world as a behavior analyst.” Professional Development Series, Association for Behavior Analysis International, Denver, CO
- 7/20/17 “Psychedelics: Extraordinary cognition and the potential to maximize human functioning.” SRI International (formerly Stanford Research Institute), SRI Technology Council, Super-Human Intelligence and Creativity Workshop, Menlo Park, CA
- 8/18/17\* “Recent clinical research on psilocybin.” Telluride Mushroom Festival, Telluride Institute, Telluride, CO.  
\*Invited and initially scheduled; did not attend for family reasons.
- 3/20/18 “5-HT<sub>2A</sub> agonist psilocybin in addiction treatment.” Clinical Research Seminar Series, Division of Intramural Clinical and Biological Research (DICBR), National Institute on Alcohol Abuse and Alcoholism (NIAAA), Bethesda, MD
- 4/12/18 “Sex, drugs and risk behavior: Decision making and pharmacology underlying sexual risk.” College of Health and Human Performance, University of Florida, Gainesville, FL

- 4/28/18\* "Behavioral processes underlying addiction and risk behavior." Kansas Association for Behavior Analysis, Lawrence, KA. \*Invited but declined due to competing invitation.
- 4/26/18 "Psilocybin in the treatment of cancer-related depression and anxiety." US Oncology Research, Advanced Therapeutics Program (ATP) Annual Scientific Retreat (ATP is the phase I trial team for McKesson Specialty Health US Oncology Research), San Diego, CA
- 5/25/18 "Behavioral processes underlying sexual risk behavior: The importance of domain specificity in clinically relevant discounting research." Society for the Quantitative Analysis of Behavior, San Diego, CA
- 7/19/18 "Applying behavioral economics to addiction, sexual risk behavior, and tobacco regulatory science." Vermont Center on Behavior and Health, Annual Summer Trainee Scientific Retreat, University of Vermont, for Burlington, VT
- 10/10/18 "Psilocybin and behavioral science." The Theory and Practice of Psychedelic Medicine, co-sponsored by Harvard Medical School, the Harvard Brain Initiative, and the Broad Institute of Harvard and Massachusetts Institute of Technology (MIT), Harvard University, Cambridge, MA
- 4/4/19 "Psilocybin effects on mystical-type experience, cancer-related depression and anxiety, and addiction." Department of Psychology, Saint Anselm College, Goffstown, NH
- 4/12/19 "The effect of drug checking on propensity to consume unknown or unintended substances." Drug-checking for Saving Lives Conference. Department of Psychology, Columbia University, New York, NY
- 4/30/19 "Psychedelic research." Milken Institute, Global Conference. Los Angeles, CA
- 5/4/19 "Research on the psychedelic drug psilocybin." Association of Health Care Journalists, Annual Conference, Baltimore, MD
- 5/20/19 "Psilocybin research." Aspen Institute, Society of Fellows Forum on Breakthroughs in Brain Health and Medicine, Washington, DC
- 7/17/19 "Therapeutic research with psilocybin." Seminar: Repurposing Abused Drugs for Treatment of Psychiatric Disorders, Departments of Pharmacology and Psychiatry, Wayne State University. Detroit, MI
- 8/10/19 "Psychedelics to economics: expanding the field of psychopharmacology." Division 28 Presidential address at the American Psychological Association Annual Convention. Chicago, IL
- 11/8/19 "Association of Multidisciplinary Education and Research in Substance Use and Addiction (AMERSA), Boston, MA
- 11/15/19 "Behavioral economics and tobacco/nicotine policy." Pioneers in Biomedical Research Seminar Program, Fralin Biomedical Research Institute (FBRI) at Virginia Tech Carillion School of Medicine, Roanoke, VA \*Scheduled
- 11/21-22/19 "Trial design and outcome considerations when studying psychedelic agents as treatments for opioid use disorder." Analgesic, Anesthetic, and Addiction Clinical Trial Translations, Innovations, Opportunities, and Networks.
- 12/4/19 "Psilocybin in the treatment of mental illness." Grand Rounds at the Department of Psychiatry, University of Utah. Salt Lake City, UT \*Scheduled
- 12/17/19 "Psychedelics and behavior change." Harvard/McLean Hospital's Neuroscience Seminar Series. Cambridge, MA
- 1/10/19 "Behavioral Pharmacology of 5-HT<sub>2A</sub> receptor agonist psilocybin." Grand Rounds at the Department of Psychiatry, University of Vermont. Burlington, VT \*Scheduled
- 2/28/20 "Therapeutics effects of the psychedelic 5-HT<sub>2A</sub> receptor agonist psilocybin." Center for Neuroscience Initiative, Auburn University. Auburn, AL.
- 3/20/20\* "Psychedelic Research: Experimental and Therapeutic Effects." University of Richmond, Department of Psychology. Richmond, VA. \*Postponed due to COVID
- 4/45/20 Panel participant: "How can we support psychedelic-friendly addiction recovery groups that are accessible, inclusive and affordable?" at the virtual Psychedelic Liberty Summit. <https://chacruna.net/psychedelic-liberty-summit/>
- 5/2/20 "Psychedelic medicine." Psychedelics 101 virtual conference. <http://futureofpsychedelics.com>
- 5/23/20 Presentation as the recipient of the Society for the Advancement of Behavior Analysis Award for Effective Presentation of Behavior Analysis in the Mass Media. Association for Behavior Analysis International annual convention, Washington DC.
- 6/5/20 "Psychedelic science." Psyched 2020 virtual conference. <https://www.eventbrite.com/e/psyched-2020-tickets-79212062411>
- 6/17/20 "Therapeutic effects of psilocybin." Psychedelic Opportunity Summit virtual conference. <https://www.psychedelicevent.com>
- 6/22/20 "Psychedelics as Medicine." Keynote address for the Prohibition Partners Live virtual conference.



<https://prohibitionpartners.live/agenda/>

- 8/27/20 Panel participant: . “The Little Fungi That Could: The Big Promise of a Small Mushroom” Vail Symposium. <https://vailsymposium.org/events/the-little-fungi-that-could-the-big-promise-of-a-small-mushroom/>
- 9/18/20 “Psychedelic Science: Behavioral and Therapeutic Effects of Psilocybin.” University of Kansas Cofrin Logan Center for Addiction Research and Treatment seminar. <https://addiction.ku.edu/matthew-johnson>
- 10/21/20 “With a little help ... All about psychedelics” the Spirituality & Science Forum 2020: Awakening to Transformation by Krueger & Lee. <https://www.kruegerandlee.com/awakening-transformation>
- 10/22/20 “Behavioral and therapeutic effects of psilocybin.” Wake Forest School of Medicine’s (WFMSM) Center for Research on Substance Use and Addiction (CRSUA), Winston-Salem, NC.
- 11/14/20 “Psilocybin: Risks, Abuse Liability, and Scheduling.” New York University Psychedelic Medicine 2020
- 12/1/20 Rationale for developing the psychedelic compound psilocybin for the treatment of stimulant use disorders and comorbid disorders.” Mini Symposium National Institute on Drug Abuse Clinical Trials Network (NIDA CTN) Stimulant Task Force.
- 12/3/20 “Psychedelic Research at Johns Hopkins.” YPO (<https://www.ypo.org>) Psychedelic Medicine for Mental Health Group’s Webinar. <https://www.youtube.com/watch?v=0LM2vR-aDlc>
- 2/2/21 “Psilocybin Treatment OF Cancer-Related Depression and Anxiety.” Houston Methodist Cancer Center, Houston Methodist Hospital, Texas Medical Center. Oncology Grand Rounds. Houston, TX
- 2/10/21 “Psilocybin: Behavioral and Therapeutic Effects.” Department of Pharmacology, University of Texas Health San Antonio. <https://lsom.uthscsa.edu/pharmacology/events/2742-2/>
- 2/25/21 Panel participant: “Symposium on Psychedelic Medicine.” University of Baltimore. <https://www.youtube.com/watch?v=6dGdoVXzYMo>
- 3/2/21 “The Latest Psilocybin Research.” Psychedelic Summit. <https://www.youtube.com/watch?v=Q-lsoIh7RIw>
- 3/3/21 “Psychedelics in Psychiatry.” Psychiatric Society of Delaware. <https://youtu.be/0YuPfffeSvA?t=7118>
- 3/16/21 “Psychedelics in Psychiatry.” Stanford University lecture series Introduction to Psychedelic Medicine.
- 4/9/21 “Psilocybin: Behavioral and Therapeutic Effects.” Department of Psychological Science at the University of Vermont Colloquium.
- 4/12-13/21 “Use of Psilocybin for Depression.” Duke-FDA Virtual Workshop | Development and Regulation of Psychedelics for Therapeutic Use
- 4/29/21 Panel participant: “Clinical Trials & Real World Evidence.” Psychedelic Capital. <https://microdose.buzz/shop/psychedelic-capital/psychedelic-capital-apr-2021/>
- 5/21/21 “Pitfalls of Psychedelic Medicine.” Los Angeles Medicinal Psychedelics Society Symposium 2021. <https://www.lampss.org/matthew-johnson/>
- 5/21/21 Panel participant: “Psychedelic Medicines for the Treatment of Substance Use Disorders.” Los Angeles Medicinal Psychedelics Society Symposium 2021. <https://www.lampss.org/agenda>

### International

- 10/6/12 “A systematic research program examining psilocybin, mystical experience, personality change, adverse effects, and therapeutic applications.” Open Foundation, Interdisciplinary Conference on Psychedelic Research (<http://www.stichtingopen.nl/past-events/icpr-2012/>). I was the only speaker from a U.S. university to speak at this two-day conference. Travel expenses covered by event sponsor. Amsterdam, Netherlands
- 7/12/15 “Psilocybin in the treatment of tobacco addiction.” Breaking Convention, 3<sup>rd</sup> International Conference on Psychedelics, University of Greenwich, Old Royal Naval College. Breaking Convention is a UK charity which hosts a biennial academic conference bringing together multiple disciplines associated with the research of psychedelic substances (<http://www.breakingconvention.co.uk/about/>). Travel expenses covered by event sponsor. London, UK
- 7/14/15 “5-HT<sub>2A</sub>R agonists in the treatment of addiction.” Department colloquium (sole speaker), Centre for Neuropsychology, Imperial College London. Travel expenses covered by event sponsor. London, UK
- 9/19/15 “Psilocybin and mystical experience: Effects on cancer-related anxiety & depression, meditation, and addiction.” Transpersonal Psychology Section 2015 Conference (Keynote speaker), British Psychological Society. Travel expenses covered by event sponsor. Cloughton, UK

- 9/22/15 “Psilocybin as a medication to facilitate behavior change in addiction and cancer related anxiety and depression.” Nordic Congress of Psychiatry. Symposium presentation. Travel covered by Lundbeckfonden (<http://www.lundbeckfonden.com>). Copenhagen, Denmark
- 11/10/17\* “Psilocybin in the treatment of smoking cessation and other forms of addiction.” Society for the Study of Addiction Annual Conference. Symposium presentation. Travel expenses covered by event sponsor. Newcastle, UK. \*Invited and initially scheduled; did not attend for family reasons.
- 11/3/2017\* “Psilocybin in addiction medicine.” MDMA and psilocybin: Bridging Science and Clinical Application, Compass Pathways (<https://compasspathways.com/>). Travel expenses covered by event sponsor. Lisbon, Portugal, November 2-4, 2017. \*Invited and initially scheduled; did not attend for family reasons.
- 5/18/18 “Abuse liability of psilocybin.” Psychedelic Lessons 2018, Slovak Psychedelic Society (SAPAS). SAPAS is a multidisciplinary non-governmental organization comprised of professionals from the fields of psychology, psychotherapy and psychiatry, as well as other disciplines (<https://sapas.sk/en/about-sapas/>). Travel expenses covered by event sponsor. Bratislava, Slovakia
- 5/19/18 “Clinical psychedelic research at Johns Hopkins: Review and update.” Psychedelic Lessons 2018, Slovak Psychedelic Society (SAPAS). SAPAS is a multidisciplinary non-governmental organization comprised of professionals from the fields of psychology, psychotherapy and psychiatry, as well as other disciplines (<https://sapas.sk/en/about-sapas/>). Travel expenses covered by event sponsor. Bratislava, Slovakia
- 6/23/18 “Psychedelic research at Johns Hopkins.” Beyond Psychedelics (A joint project of researchers based at the Czech National Institute of Mental Health with members of other collaborating organizations; <http://www.beyondpsychedelics.cz/concept/>). Travel expenses covered by the event sponsor. Prague, Czech Republic
- 10/12/18 “The re-emergence of research on psychedelics: Recent clinical findings with psilocybin.” 2018 Colloquium on Psychedelic Psychiatry, Swedish Network for Psychedelic Science (Swedish 'Nätverket för Psykedelisk Vetenskap' or 'NPV'; <http://cpp2018.se/>). Travel expenses covered by event sponsor. Stockholm, Sweden.
- 10/4/18 “Clinical research with psilocybin and other psychedelics.” BergamoScienza Science Festival, Associazione BergamoScienza ([www.bergamoscienza.it](http://www.bergamoscienza.it)). Travel expenses covered by event sponsor. Bergamo, Italy.
- 12/8/18 “5HT<sub>2A</sub> receptor agonist psilocybin in the treatment of cancer-associated depression and anxiety.” Psychedelics and Spiritual Healing at the End of Life, University of Ottawa. Travel expenses covered by event sponsor. Ottawa, Ontario, Canada.
- 6/25/19 “Presentation title: Effects of the psychedelic compound psilocybin on mystical experience and therapeutics.” Psychedelics: Phenomenology, Neurobiology and Clinical Use Workshop, The Science of Consciousness, Annual Conference, University of Arizona Center for Consciousness Studies. Travel expenses covered by event sponsor. Interlaken, Switzerland.
- 6/27/19 “Psychedelics and positive behavior change: The role of mystical experience.” Plenary talk, The Science of Consciousness, Annual Conference, University of Arizona Center for Consciousness Studies. Travel expenses covered by event sponsor. Interlaken, Switzerland.
- 6/28/19\* “Modern research with psychedelics.” Departments of Social and Political Science, and Psychiatry, University of Melbourne, Melbourne, Australia. \*Remote web-based presentation
- 7/1/19 “5-HT<sub>2A</sub> agonist psilocybin in the treatment of tobacco addiction.” Department of Psychiatry, University of Oxford. Travel expenses covered by event sponsor. Oxford, UK.
- 9/5-7/19 “Frontiers in psychedelic research.” InSight 2019 – Integrating the Science and Practice of Psychedelic States, MIND Foundation (<https://mind-foundation.org/>). Travel expenses covered by event sponsor. Berlin, Germany.
- 9/10/19 “Basic and therapeutic research with 5-HT<sub>2A</sub> agonist psilocybin.” Karolinska Institute. Travel expenses covered by event sponsor. Stockholm, Sweden.
- 9/21/19 “Clinical research with psilocybin.” Mapping the Mind: Toronto Psychedelic Science Conference. Travel expenses covered by event sponsor. Toronto, Ontario, Canada.
- 9/23/19 “The future of psychedelics in the treatment of mental illness.” Extraordinary Future Conference. Cambridge House International, Inc. Travel expenses covered by event sponsor. Vancouver, BC, Canada.
- 6/5/20\* “Behavioral science of addiction, decision making, and psilocybin.” Amsterdam Institute for Social Science Research (AISSR), University of Amsterdam. Travel expenses covered by event sponsor. Amsterdam, Netherlands. \* Originally schedule with travel expenses covered by event sponsor but cancelled due to COVID-19

- 6/11/20 "Psychedelics in the Treatment of Addiction" 14th Annual Albatros Meeting. Paris, France. \* Originally schedule in person with travel expenses covered by event sponsor but converted to virtual due to COVID-19
- 9/25/20 "Psychedelics as Behavior Change Agents." Interdisciplinary Conference on Psychedelic Research, the OPEN Foundation. The OPEN Foundation is an independent not-for-profit NGO with the goal to stimulate therapeutic research with psychedelics. Haarlem, The Netherlands. \*Originally schedule in person with travel expenses covered by event sponsor but converted to virtual due to COVID-19
- 10/27/20 "Psychedelics in Treating Addiction." Psytech Summit: A Global Dialogue on the Future of Psychedelic Medicine. <https://psytechglobal.com/psytech-summit-replay/>
- 10/29/20 "Psychedelics in the Treatment of Addiction." 14th Annual Albatros Meeting, Paris, France. <https://www.youtube.com/watch?v=HJaGNyTpvKE&feature=youtu.be>
- 3/23/21 Panel participant: "Mind Altering Medicines." World Science Festival Brisbane, at the Queensland Museum. Brisbane, Australia. Originally schedule with travel expenses covered by event sponsor but converted to virtual due to COVID-19. <https://www.youtube.com/watch?v=Am4naLpOxuw>
- 4/28/21 "Psychedelic Medicine: Future Directions & Challenges." Psychedelic Science Webinar at Karolinska Institute in Stockholm, Sweden, <https://studenteriforskning.se>
- 5/19/21 Panel participant: "5-MeO-DMT: Past, Present & Future" for the Maudsley Psychedelic Society. The Institute of Psychiatry, Psychology and Neuroscience, King's College London. London, UK.
- 9/10/21 Panel participant: "Building the Mental Health Treatments of the Future - Between Neurobiological Effects and Phenomenological Diversity." Insight 2021: Psychedelic Research & Therapy, from Science to Implementation. Berlin, Germany. <https://insight-conference.eu> Originally schedule with travel expenses covered by event sponsor but converted to virtual due to COVID-19.
- 9/11/21 Panel participant: "Assessing the Value of Psychedelic Therapies to Payers and Society." Insight 2021: Psychedelic Research & Therapy, from Science to Implementation. Berlin, Germany. <https://insight-conference.eu> Originally schedule with travel expenses covered by event sponsor but converted to virtual due to COVID-19.
- 9/11/21 "Psychedelics, Psychotherapy, and Pitfalls." Insight 2021: Psychedelic Research & Therapy, from Science to Implementation. Berlin, Germany. <https://insight-conference.eu> Originally schedule with travel expenses covered by event sponsor but converted to virtual due to COVID-19.
- 9/12/21 Panel participant: "A Glimpse of the Bigger Picture - Consciousness in Culture and Medicine." Insight 2021: Psychedelic Research & Therapy, from Science to Implementation. Berlin, Germany. <https://insight-conference.eu> Originally schedule with travel expenses covered by event sponsor but converted to virtual due to COVID-19.
- 11/17-20/21\* "Psychedelics in Mental Health Treatment" International Summit on Psychedelic Therapies for Mental Illness. Mind Medicine Australia. Melbourne, Australia \*Scheduled

## OTHER PROFESSIONAL ACCOMPLISHMENTS

### Other

#### Published Abstracts (indexed by Google Scholar)

1. Griffiths RR, Suesse P, **Johnson MW**. Ramelteon and triazolam in humans: behavioral effects and abuse potential. *Sleep*. 2005;28:A44-A44.
2. Bradstreet MP, **Johnson MW**, MacLean KA, Griffiths RR. Characterization of challenging experiences (i.e., bad trips) after ingesting psilocybin. *Drug Alcohol Depend*. 2014;140:e18-e19.
3. Garcia-Romeu AP, **Johnson MW**, Griffiths RR. Examining the psychological mechanisms of psilocybin-assisted smoking cessation treatment: A pilot study. *Drug Alcohol Depend*. 2014;140:e66.
4. Nichols D, **Johnson MW**, Griffiths RR, Henningfield J. The path toward making psilocybin available for medical use: New findings and analyses related to abuse potential and safety. *Neuropsychopharmacology*. 2014;39:S579-80.
5. Schacht RL, **Johnson MW**, Strain EC, Mintzer M. Effects of working-memory training in methadone maintenance patients. *Drug Alcohol Depend*. 2014;140:e197.
6. Umbricht A, Mintzer M, Rass O, Bigelow GE, **Johnson MW**, Strain EC, Tompkins DA. Correlates of impaired cognitive performance in cocaine-and opioid-dependent patients. *Drug Alcohol Depend*. 2014;140:e230.
7. Barrett FS, Bradstreet MP, Leoutsakos J, **Johnson MW**, MacLean KA, Jesse R, Griffiths RR. The Challenging Experience Questionnaire: Characterization of acute adverse reactions to psilocybin. *Drug Alcohol Depend*. 2015;146:e218.
8. Barrett FS, **Johnson MW**, Griffiths RR. Validation of the revised mystical experiences questionnaire in experimental sessions with psilocybin. *Drug Alcohol Depend*. 2015;156:e16.

9. Carbonaro TM, Barrett FS, MP Bradstreet, **Johnson MW**, MacLean KA, Jesse R, **Johnson MW**, Griffiths RR. Survey study of challenging experiences after ingesting psilocybin mushrooms: Demographics and phenomenology. *Drug Alcohol Depend.* 2015;146:e239-e240.
10. Carbonaro TM, Klinedinst M, **Johnson MW**, Griffiths RR. Comparative phenomenology of psilocybin experiences in research and non-research settings. *Drug Alcohol Depend.* 2015;156:e36-e37.
11. Garcia-Romeu AP, Griffiths RR, Johnson MW. Psychedelic-facilitated smoking cessation: An online survey. *Drug Alcohol Depend.* 2015;146:e120.
12. Garcia-Romeu AP, Noorani T, Griffiths RR, **Johnson MW**. Long-term follow-up of psilocybin-facilitated smoking cessation: Abstinence outcomes and qualitative analysis of participant accounts. *Drug Alcohol Depend.* 2015;156:e78.
13. Koffarnus MN, **Johnson MW**, Wesley MJ, Lohrenz T, Montague PR, Bickel WK. Cocaine-dependent adults are more likely than controls to choose immediate unsafe sex over delayed safe sex. *Drug Alcohol Depend.* 2015;146:e161.
14. Rass O, Pacek LR, Johnson PS, **Johnson MW**. Use patterns, perceptions of relative harm, and gender effects in dual users of electronic and tobacco cigarettes. *Drug Alcohol Depend.* 2015;156:e186.
15. Sweeney MM, Rass O, Johnson PS, **Johnson MW**. Development of a prospective memory training program for substance use treatment. *Drug Alcohol Depend.* 2015;156:e217-8.
16. Barrett FS, **Johnson MW**, Griffiths RR. Subjective effects of psilocybin predict next-day differences in default mode network and medial temporal lobe functional connectivity. 2016. *Neuropsychopharmacology.* 2016;41:S200-S201.
17. Bickel WK, Higgins ST, **Johnson MW**, Borland R. The behavioral economics of health behavior change: New findings and application. *International Journal of Behavioral Medicine.* 2016;23:S34-S34.
18. Koratana A, Dredze M, Chisolm MS, **Johnson MW**, Paul MJ. Studying Anonymous Health Issues and Substance Use on College Campuses with Yik Yak. Association for the Advancement of Artificial Intelligence (AAAI) Workshop: WWW and Population Health Intelligence. 2016.
19. Barrett FS, Carbonaro T, **Johnson MW**, Griffiths RR. Effects of the classic hallucinogen psilocybin and the dissociative hallucinogen dextromethorphan on cognition. *Neuropsychopharmacology.* 2017;43:S287-S288.
20. Barrett FS, **Johnson MW**, Griffiths RR. Psilocybin in long-term meditators: Effects on default mode network functional connectivity and retrospective ratings of qualitative experience. *Drug Alcohol Depend.* 2017;171:e15-e16.
21. Carbonaro TM, **Johnson MW**, Griffiths RR. Comparison of anomalous experiences after ingesting psilocybin mushrooms in research and non-research settings. *Drug Alcohol Depend.* 2017;171:e34.
22. Garcia-Romeu AP, Griffiths RR, **Johnson MW**. Psychedelic-associated addiction remission: An online survey. *Drug Alcohol Depend.* 2017;171:e69.
23. **Johnson MW**. Alcohol intoxication increases delay discounting for sexual but not monetary decisions. *Alcoholism-Clinical and Experimental Research.* 2017;41;307A.
24. **Johnson MW**, Herrmann ES, Johnson PS, Sweeney MM. Cocaine decreases preference for condom use as function of delayed condom availability and STI risk. *Drug Alcohol Depend.* 2017;171:e97.
25. Sweeney MM, **Johnson MW**. Age and working memory predict delay discounting in adolescents in treatment for cannabis use disorders. *Drug Alcohol Depend.* 2017;171:e200.
26. McKenna M, Fedota J, Garcia-Romeu AP, **Johnson MW**, Griffiths RR, Stein E. Psilocybin improves cognitive control and downregulates parietal cortex in treatment-seeking smokers. *Biological Psychiatry.* 2018;83 (9):S231-S232.